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ABSTRACT 
By applying a diversity oriented synthesis strategy for the search of new antagonists of the 
thrombin receptor PAR1, a series of peptide-based ureas and thioureas, including analogues 
of the PAR1 reference antagonist RWJ-58259, has been designed and synthesized. The 
general synthetic scheme involves reduction of basic amino acid-derived amino nitriles by 
hydrogen transfer from hydrazine monohydrate in the presence of Raney Ni, followed by 
reaction with diverse isocyanates and isothiocyanates, and protecting group removal. All new 
compounds have been evaluated as inhibitors of human platelet aggregation induced by the 
PAR1 agonist SFLLRN. Some protected peptide-based ureas displayed significant antagonist 
activity. 
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1. Introduction 
  In addition to the key role of thrombin in the blood coagulation cascade [1], this serine 
protease regulates multiple effects on an increasing variety of cells, such as: platelets [2, 3], 
endothelial and smooth muscle cells [2, 4], neurons and astrocytes in the nervous system [2, 
4-7], immune and inflammatory cells [8, 9], osteoblasts [10], and tumor cells [11-14]. These 
cellular effects are mainly mediated by the activation of the protease-activated receptor PAR1 
[15]. This is a G-protein coupled receptor (GPCR) that is activated by the thrombin-catalyzed 
cleavage of the N-terminal extracellular domain at the Arg
41
/Ser
42
 peptide bond, which 
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unveils the recognition sequence SFLLRN that acts as a tethered activation ligand. The 
conformational changes induced by activation favors the coupling of PAR1 with 
heterotrimeric G-proteins, which consequently activate complex cellular signaling cascades 
[16, 17]. 
Since PAR1 is mainly expressed in platelets, where its activation induces aggregation, it 
has been proposed that PAR1 antagonists could be good antithrombotic agents without the 
hemorrhagic drawbacks of thrombin inhibitors. Based on this suggestion, up to now, PAR1 
antagonists have been searched almost exclusively in relation to the cardiovascular system [3, 
18, 19].  However, numerous studies have shown that PAR1 is overexpressed in invasive and 
metastatic tumors and that its expression levels directly correlate with the degree of 
invasiveness of the cancer [20-28].  Based on these facts, this receptor is starting to be also 
considered a promising target for cancer therapy [15], particularly in the search of 
angiogenesis inhibitors [29].  
The first potent PAR1 antagonists were SFLLRN-based peptidomimetic ureas, represented 
by the optimized antagonist RWJ-58259 (Figure 1) [19]. This antagonist showed protection 
against thrombus formation in nonhuman primates, providing the first in vivo proof for 
supporting the potential clinical utility of PAR1 antagonists, although, its low oral 
bioavailability stopped its clinical development [19]. Later, several laboratories have reported 
a few series of antagonists obtained from HTS of diverse libraries of non-peptide small 
molecules, followed by optimization [19, 30]. The most advanced of these antagonists is 
SCH-530348 (named vorapaxar, Figure 1), derived from the natural product himbacine, 
which currently is undergoing Phase III clinical trials in patients with acute coronary 
syndrome and in patients with atherosclerosis [31-33]. Up to now, there is not structural 
information on the binding sites of these PAR1 antagonists to be used for structure-based 
design of new antagonists. However, recent mutagenesis studies on thrombin and/or PAR1 
[34-42], X-ray of thrombin crystallized with diverse N-terminal fragments of PAR1 [43, 44], 
and NMR studies on the (Ala
26
-Hse
103
) N-terminal sequence of PAR1 [45] have shown that 
the first thrombin/PAR1 interaction is produced between the exosite I of thrombin and the 
hirudin-like sequence of PAR1 (K
51
YEPF
55
), and that this first interaction is essential and 
determinant for high affinity. It seems that the hydrophobic residues F34, I82, L65 and Y76, 
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Fig. 1. Selected PAR1 antagonists and proposed new structures 
 
and the basic residues R67 and R73, of the exosite I of thrombin are important for high 
affinity. Taking into account this knowledge, we started a project directed to the search of 
new PAR1 antagonists based on these hot spots of the exosite I of thrombin for PAR1. As 
these hot spots are discontinuous and are not localized in a defined secondary structure, we 
decided to use a diversity oriented synthesis (DOS) strategy for the search of 
peptidomimetics. For this purpose, we planned the synthesis of diverse small directed libraries 
of different scaffolds able to display, at least, one or two aromatic groups and one or two 
basic groups at variable distances and orientations. Among these structures, our first objective 
was the synthesis of ureas and thioureas of general formula A, which could be considered as 
analogues of the reference antagonist RWJ-58259. To this aim, we devised a synthetic 
scheme using basic amino acid derived α-amino nitriles 1 and 2 (Figure 1) as key diversity 
generation intermediates [46]. Herein, we report the synthesis of ureas and thioureas A and 
their evaluation as human PAR1 antagonists in a platelet aggregation assay.  
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2. Results and discussion  
2.1. Synthesis 
The proposed general synthetic scheme for the preparation of ureas and thioureas A 
involves cyano-reduction of the protected α-amino nitriles 1 and 2, followed by reaction of 
the resulting primary amines with isocyanates or isothiocyanates and subsequent removal of 
protecting groups. The starting basic amino acid-derived α-amino nitriles 1 and 2 were 
obtained by a modified Strecker reaction as (1:1) epimeric mixtures at the cyano-supporting 
stereocenter, except for the arginine derivatives 1c, which were obtained in an (R)/(S) ratio of 
(1:3) [47]. Only the epimeric mixtures (RS)-1a,b could be chromatographically resolved into 
the respective (R)- and (S)-epimers. Therefore, (RS)-1c and (RS)-2a,b were used as such 
epimeric mixtures through the synthetic pathway.  
Scheme 1.  Reagents and conditions: (a) H2, Pd(C), MeOH, rt. (b) H2, Raney Ni, MeOH, rt. (c) NH2NH2·H2O,  
Raney Ni, MeOH or EtOH, T and time as indicated in Table 1. (d) PhNCO, CH2Cl2, 0ºC. (e) 3M HCl, EtOAc, rt. 
 
The epimeric mixture (RS)-1a was used as a model for optimizing the cyano reduction. 
Initially, this was attempted by 10% Pd(C) or Raney Ni catalyzed hydrogenation. However, as 
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shown in Scheme 1 and Table 1, the HPLC MS analysis of the crude reaction showed that the 
expected primary amines (RS)-3a were obtained along with variable percentages of 5a and 
6a, resulting from retro-Strecker reaction and reduction of the intermediate imine after 
removal of HCN, respectively. The difficulties in the purification of (RS)-3a from the crude 
reaction mixtures moved us to try the reduction by hydrogen transfer, using hydrazine 
monohydrate as hydrogen source and Raney Ni as catalyst [48]. After the study of reaction 
conditions (Table 1), the formation of the side product 6a could be completely avoided, but 
not that of the retro-Strecker reaction 5a. This side reaction was minimized to a 5 % by 
carrying out the reduction under refluxing MeOH for 5 min, using 20 equivalents of 
hydrazine monohydrate and 100 mg/mmol of Raney Ni (entry 7). These optimized conditions 
were applied to the reduction of the other starting α-amino nitriles. It is interesting to point out 
the importance of the Raney Ni activation, as well as the efficiency of the stirring, to make the 
reduction as faster as possible, in order to minimize the presence of the amino nitrile within 
the reaction medium, for minimizing the retro-Strecker reaction. Besides, in the 
phenylacetaldehyde derivatives 3 (m =1), the reduction of the (R)-epimer was slower than that 
of the corresponding (S)-epimer and, consequently, its percentage of degradation via retro-
Strecker was significantly higher [see for example different yields for reduction of (R)- and 
(S) epimers of 1a and 1b in Table 2]. In the case of the Arg derivative 3c, the difference in 
reactivity between epimers made that the minor (R)-epimer were lost in the reduction.  
Table 1  
Optimization of the reduction conditions for (RS)-1a 
Entry Catalyst H2 source T (ºC) t (min) 
Yield (%)
a
 
(RS)-3a 5a 6a 
1 10 % Pd(C) H2 rt 24 h 80 8 12 
2 Raney Ni (100 mg/mmol) H2 rt 24 h 54 6 40 
3 Raney Ni (100 mg/mmol) NH2NH2·H2O 85 30 37 63 - 
4 Raney Ni (100 mg/mmol) NH2NH2·H2O rt 30 67 33 - 
5 Raney Ni (200 mg/mmol) NH2NH2·H2O rt 30 73 27 - 
6 Raney Ni (100 mg/mmol) NH2NH2·H2O rt 90 92 8 - 
7 Raney Ni (100 mg/mmol) NH2NH2·H2O 65 5 95 5 - 
a 
Determined by HPLC-MS analysis. 
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Due to the difficulties found in the separation of the primary amines 3 and 4 from the side 
product of the retro-Strecker reaction 5, the crude reduction mixtures were initially used 
without purification for the synthesis of the desired ureas 8 and 9. However, the difficulties in 
the purification of these ureas remained, and several column chromatographies were required 
for their separation from the ureas 10, byproducts derived from the amino amides 5, with 
considerable loss in the yield. Only the epimeric mixture of ornithine-derived ureas (RS)-9a 
could be resolved during this chromatographic purification. In view of these results, to avoid 
the purification difficulties, we decided to isolate the reduction intermediate amines as the 
corresponding Fmoc-derivatives. This strategy was studied in the phenylacetaldehyde 
derivatives (R)- and (S)-3a,b and (RS)-3c. At this point, it is important to note that when the 
Fmoc-protection was carried out under the standard basic conditions, using Na2CO3 as HCl 
acceptor in dioxane/water [49], almost complete epimerization of one of the two chiral centers 
was observed. This epimerization was completely avoided by using propylene oxide as HCl 
acceptor in CH2Cl2, to obtain the Fmoc-protected amines (R)- and (S)-12a,b and (S)-12c in 
30-72% overall yield from the amino nitriles (R)- and (S)-3a,b and (RS)-3c (Scheme 2).  
Scheme 2. Reagents and conditions: (a) NH2NH2·H2O, Raney Ni, MeOH, 65 ºC. (b) Fmoc-Cl, propylene oxide, 
CH3CN, 0ºC. (c) Et2NH, CH2Cl2, rt. (d) R
2
NCO, CH2Cl2, 0ºC. (e) 3M HCl, EtOAc, rt. 
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The Fmoc-removal in 12a-c, followed by reaction with different aromatic isocyanates 
(Scheme 2) led to the desired ureas 8 and 13-16 in significantly higher overall yields than by 
the direct synthesis of the urea after the cyano-reduction (compare yields of methods A and B 
in Table 2).  
Table 2 
Optimization of the synthesis of ureas 8, 9 and 13-17 
Amino nitrile Diamine
a
  Urea
b
 
Nº %  Nº A (%)
c
 B (%)
d
 
(RS)-1a (1:1)
e
 (RS)-3a (1:3)
e
 74  (RS)-8a (1:3)
e
 36 52 
(R)-1a  (R)-3a  55  (R)-8a  - 17 
(S)-1a  (S)-3a  92  (S)-8a  - 67 
(RS)-1b (1:1)
e
 (RS)-3b (1:1.3)
e
 73  (RS)-8b (1:1.3)
e
 21 44 
(R)-1b  (R)-3b  60  (R)-8b  - 44 
(S)-1b  (S)-3b  87  (S)-8b  - 57 
(RS)-1c (1:3)
e
 (S)-3c 64  (S)-8c - 25 
(R)-1a  (R)-3a  55  (R)-13a  - 25 
(S)-1a  (S)-3a  92  (S)-13a  - 51 
(R)-1b  (R)-3b  60  (R)-14b  - 40 
(S)-1b  (S)-3b  87  (S)-14b  - 52 
(R)-1b  (R)-3b  60  (R)-15b  - 42 
(S)-1b  (S)-3b  87  (S)-15b  - 61 
(R)-1b  (R)-3b  60  (R)-16b  - 40 
(S)-1b  (S)- 3b  87  (S)-16b  - 62 
(RS)-2a (1:1)
e
 (RS)-4a (1:1)
e
 74  (RS)-9a (1:1)
e
 27 - 
(RS)-2b (1:1)
e
 (RS)-4b (1:1)
e
 74  (RS)-9b (1:1)
e
 29 - 
a
Yields determined by HPLC-MS analyses.  
b
Isolated yields. 
 
c
Overall yield of reduction, followed by reaction with the corresponding isocyanate (Method A). 
 
d
Overall yield of reduction, followed by sequential Fmoc-protection, isolation, Fmoc-deprotection, and reaction 
with the corresponding isocyanate (Method B). 
 
e
(R:S)-epimer ratio. 
 
Removal of the N-Boc protection of the basic side chain in the Orn and Lys derived ureas 
8a,b, 9a,b and 13a,b-16b by treatment with 3M HCl solution in EtOAc, yielded the 
corresponding deprotected compounds 11a,b and 17a,b-21b (Schemes 1 and 2). In view of 
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the poor biological results of these deprotected ornithine and lysine derivatives (see below) 
and the low overall yield of the arginine-derived urea 8c, this urea was not deprotected. 
The lysine-derived Fmoc protected diamine 12b was also used for the synthesis of the 
PAR1 reference antagonist RWJ-58259 analogue (S)-25b (Scheme 3). This urea was 
synthesized by applying our recently reported procedure for the preparation of RWJ-58259 
[50]. This procedure involves the in situ formation of the indazole-derived isocyanate 23, by 
reaction of the required 6-amino-indazole 22 with triphosgene in the presence of propylene 
oxide as HCl acceptor, followed by reaction with the deprotected diamines (R)- and (S)-3b. 
Interestingly, as commented for the reduction of the starting amino nitriles, the application of 
this methodology gave considerably higher yield for (S)-24b [85 % overall from (S)-12b] 
than for its epimer (R)-24b [20 % overall yield from (R)-12b]. Due to this low yield, this 
epimer was reserved for the biological evaluation and was not deprotected. 
Scheme 3. Reagents and conditions: (a) (CCl3O)2CO, propylene oxide, THF, 0 ºC . (b) Et2NH, CH2Cl2, rt. (c) 
THF, 0 ºC. (d) 3M HCl, EtOAc, rt. 
 
The optimized method B of synthesis of urea derivatives 17a was similarly applied to the 
synthesis of the thiourea analogues (R)- and (S)-27a, by replacing the phenylisocyanate by 
phenylisothiocyanate (Scheme 4). 
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Scheme 4. Synthesis of thiourea derivatives 
2.2. Biological evaluation 
Since PAR1 is mainly expressed in platelets, to evaluate the PAR1 antagonist activity, all 
new compounds were screened as inhibitors of human platelet aggregation induced by a 30 
µM concentration of the PAR1 agonist SFLLRN. The antagonist RWJ-58259 was used as a 
reference. At a 10 M concentration this antagonist inhibited 98% the platelet aggregation. 
All compounds were tested at an initial concentration of 0.1 mg/mL (≈ 150 M). 
Unfortunately, none of the deprotected ureas or thioureas inhibited the platelet aggregation. 
However, as shown in Figure 2, some of the protected ureas, and particularly the Fmoc 
intermediates 12, showed significant inhibition. Thus, the Fmoc derivatives (S)-12a and (S)-
12c inhibited a 51 % and a 36 %, respectively, the platelet aggregation. Among the protected 
ureas and thioureas, the most potent were the urea (R)-8b and the thiourea (S)-26a, which 
showed 38 and 33 % of inhibition, respectively. Although these results do not allow to 
establish defined structure-activity relationships, it seems that in the Fmoc derivatives 12 and 
thioureas 26a, the (S)-epimers showed higher inhibition % than the respective (R). However, 
in the case of the urea derivatives there is not a clear stereochemistry-activity relationship, as 
the results varied depending on the urea substitution. At this position, the phenyl group was 
the best (compare ureas 8b with 14b-16b and 24b). Respecting the influence of the basic 
amino acid moiety, from the comparison of analogue (S)-epimers, in the Fmoc-derivatives 12, 
the order of activity was Orn(a) >Arg(c) > Lys(b), while in the urea-derivatives 8, the order 
was Arg(c) ≥ Lys(b) > Orn(a).  
In the structural comparison of the inactive indazole-derived urea (S)-25b with the family 
of peptidomimetic urea PAR1 antagonists, to which the reference antagonist RWJ-58259 
belongs [51], the main difference is the replacement of the di(F)-Phe residue of RWJ-58259 
by the 1-amino-3-phenyl-propan-2-yl moiety in (S)-25b (see Figure 1). This replacement 
involves the loss of the carbonyl group of the peptide bond, which could be important for the 
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interaction with the PAR1 receptor, participating in H-bond formation or for the appropriate 
orientation of the pharmacophoric groups.  
 
 
 
 
 
 
 
 
Fig. 2. Inhibition (%) of human platelet aggregation induced by a 30 M concentration of SFLLRN 
 
3. Conclusion 
A series of peptide-based ureas and thioureas, including analogues of the PAR1 reference 
antagonist RWJ-58259, has been designed and synthesized as potential PAR1 antagonists. A 
DOS strategy has been applied for the synthesis of these urea derivatives, consisting of 
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reduction of basic amino acid-derived amino nitriles, followed by reaction with diverse 
isocyanates or isothiocyanates. To evaluate the PAR1 antagonist activity, all new synthesized 
compounds have been screened as inhibitors of human platelet aggregation induced by the 
PAR1 agonist SFLLRN. Although none of the designed peptide-based ureas inhibited 
aggregation, some of their protected derivatives showed moderate antiaggregant activity. 
These results could be a good clue for the search of new potent PAR1 antagonists and to 
explore the thrombin/PAR1 interaction. 
 
4. Experimental 
4.1. General 
All reagents were of commercial quality. Solvents were dried and purified by standard 
methods. Analytical TLC was performed on aluminum sheets coated with a 0.2 mm layer of 
silica gel 60 F254. Silica gel 60 (230-400 mesh) was used for flash chromatography. Analytical 
RP-HPLC was performed on a Sunfire C18 (4.6×150 mm, 3.5 μm) column, with a flow rate of 
1 mL/min, using a tunable UV detector set at 214 and 254 nm and a (10-100%, 30 min) 
gradient of CH3CN (solvent A) and 0.05 % TFA in H2O (solvent B) as mobile phase. HPLC-
MS was performed on a Sunfire C18 (4.6×50 mm, 3.5 μm) column at 30°C, with a flow rate of 
1 mL/min. (10-100%, 5 min) Gradient of CH3CN with 0.08% of formic acid (solvent A) in 
0.1% of formic acid in H2O (solvent B) was used as mobile phase. Electrospray in positive 
mode was used for ionization. Melting points were taken on a Mettler Toledo M170 apparatus 
and are uncorrected. Elemental analyses were obtained on a CH-O-RAOID apparatus. Optical 
rotations were determined in a Perkin Elmer 141 polarimeter. NMR spectra were recorded 
using Varian Inova 300, Varian Inova or Mercury 400, and Varian Unity 500 spectrometers. 
The NMR spectra assignment was based on COSY, HSQC, and HMBC spectra. 
4.2. General procedure for the synthesis of basic amino acid-derived ureas. Method A. 
Synthesis of ureas (RS)-8a,b and -9a,b, and (R)- and (S)-9a 
Raney Ni (30 mg) and hydrazine monohydrate (0.186 mL, 6 mmol) were added to a 
solution of the corresponding amino nitrile (RS)-1a,b  and (RS)-2a,b (0.3 mmol) in MeOH 
(20 mL) and the resulting reaction mixture was refluxed for 5 min. Then, the mixture was 
filtered through celite, this was washed with MeOH (3×75 mL), and the filtrates were 
evaporated to dryness. The residue was dissolved in dry CH2Cl2 (10 mL) and the solution was 
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cooled at 0ºC. The corresponding isocyanate (0.3 mmol) was added to the solution that was 
stirred at this temperature for 2 h. Then, the solvent was evaporated and the residue was 
dissolved in EtOAc (50 mL). This solution was successively washed with H2O (20 mL) and 
brine (20 mL), dried over Na2SO4, and evaporated to dryness. The residue was purified by 
flash chromatography, using 20-100% EtOAc gradient in hexane as eluant to afford the ureas 
(RS)-8a,b and (RS)-9a,b. Only both epimers of the ornithine-derived ureas (R)-9a and (S)-9a 
could be separated in this purification. The two epimers of (RS)-8a,b were obtained as optical 
pure compounds from each epimer of the starting amino nitrile (R)-1a,b and (S)-1a,b, by 
applying method B described below. The characterization data of (R)-8a,b and (S)-8a,b are 
also described below. 
4.2.1. N-Boc-N-[(2R)-4-Phenyl-1-(3-phenylureido)butan-2-yl]-ornithine benzyl amide 
[(R)-9a] 
Foam (23 mg , 13 %); HPLC tR 18.54; []D
20
 +7.5 (c 0.9, MeOH); 
1
H NMR (400 MHz, 
CDCl3) δ 1.40 (s, 9H, Boc), 1.29-1.81 [m, 6H, 3-H (Bu), - and β-H (Orn)], 2.49-2.78 [m, 3H, 
2-H and 4-H (Bu)], 2.95-3.43 [m, 4H, 1-H (Bu), - and -H (Orn)], 4.32 [m, 2H, CH2 (Bn)], 
4.92 (bs, 1H, NH-Boc), 5.86, and 7.67 (2 bs, 2H, HNCONH), 6.95-7.56 (m, 16 H, Ph and NH-
Bn); 
13
C NMR (100 MHz, CDCl3) δ 28.6 (CH3, Boc and CH2, C), 31.6 (CH2, Cβ), 32.3 (CH2, 
C4), 35.7 (CH2, C3), 39.5 (CH2, C), 43.1 (CH2, C1), 43.5 [CH2, (Bn)], 57.1 (CH, C2), 58.3 
(CH, C), 79.8 (C, Boc), 119.8-129.2 (15CH, Ph), 138.5, 139.6 and 141.9 (3C, Ph), 156.2 
(HNCONH), 157.1 (CO, Boc), 175.1 (CONH); ES-MS m/z [M+1]
+
 calcd. for C34H45N5O4, 
688.35; found 688.17 (100%); Anal. calcd. for C34H45N5O4: C, 69.48; H, 7.72; N, 11.92. 
Found: C, 69.67; H, 7.86; N, 11.78. 
4.2.2. N-Boc-N-[(2S)-4-Phenyl-1-(3-phenylureido)butan-2-yl]-ornithine benzyl amide 
[(S)-9a] 
Foam (25 mg , 14 %); HPLC tR 18.89; []D
20
 +5 (c 1, MeOH); 
1
H NMR (400 MHz, 
CDCl3) δ 1.42 (s, 9H, Boc), 1.46-1.80  [m, 6H, 3-H (Bu), - and β-H (Orn)], 2.51-2.63 [m, 
3H, 2-H and 4-H (Bu)], 2.92-3.31 [m, 4H, 1-H (Bu), - and -H (Orn)], 4. 26 [dd, 1H, J = 6 
and 15 Hz, CH2 (Bn)], 4. 31 [dd, 1H, J = 6 and 15 Hz, CH2 (Bn)], 4.73 (bs, 1H, NH-Boc), 
5.84, and 7.70 (2 bs, 2H, HNCONH), 6.92-7.52 (m, 16 H, Ph and NH-Bn); 
13
C NMR (100 
MHz, CDCl3) δ 28.6 ( CH2, C), 28.7 (CH3, Boc), 32.2 (CH2, Cβ), 32.4 (CH2, C4), 35.6 (CH2, 
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C3), 40.3 (CH2, C), 42.5 (CH2, C1), 43.4 [CH2, (Bn)], 57.4 (CH, C2), 59.9 (CH, C), 80.1 (C, 
Boc), 119.6-129.2 (15CH, Ph), 138.6, 139.6 and 141.9 (3C, Ph), 156.7 (HNCONH), 157.2 
(CO, Boc), 174.9 (CONH); ES-MS m/z [M+1]
+
 calcd. for C34H45N5O4, 688.35; found 688.27 
(100%); Anal. calcd. for C34H45N5O4: C, 69.48; H, 7.72; N, 11.92. Found: C, 69.59; H, 7.82; 
N, 11.85. 
4.2.3. Nε-Boc-N-[4-Phenyl-1-(3-phenylureido)butan-2-yl]-lysine benzyl amide [(RS)-9b] 
Foam (52 mg, 29 %); HPLC tR 18.70 [(R)-9b] and 19.06 min [(S)-9b]; 
1
H NMR (400 
MHz, CDCl3) δ 1.41 and 1.43 (2s, 9H, Boc), 0.94-1.33 [m, 2H, -H (Lys)], 1.50-1.85 [m, 6H, 
- and β-H (Lys), 3-H (Bu)], 2.45-2.74 [m, 3H, 2-H and 4-H (Bu)], 2.90-3.17 [m, 2H, ε-H 
(Lys)], 3.17-3.27 [m, 1.5H, 1-H (Bu) and -H (Lys)], 3.38 [m, 0.5H, 1-H (Bu)], 4.36 [m, 2H, 
CH2 (Bn)], 4.66 and 4.84 (2bs, 1H, NH-Boc), 5.80, 7.84 and 8.10 (3 bs, 2H, HNCONH), 6.86-
7.54 (m, 16 H, Ph and NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 22.9 (CH2, C), 26.4 and 28.5 
(CH3, Boc), 29.8 (CH2, C), 32.1 (CH2, C4), 33.0 (CH2, Cβ), 34.8 (CH2, C3), 40.0 (CH2, Cε), 
42.0 and 43.0 (CH2, C1), 43.3 [CH2, (Bn)], 56.9 and 58.8 (CH, C2), 60.1 (CH, C), 80.1 (C, 
Boc), 119.1-128.9 (15CH, Ph), 139.1 and 141.3 (3C, Ph), 156.2 and 156.7 (2CO, Boc and 
HNCONH), 174.9  (CONH); ES-MS m/z [M+1]
+
 calcd. for C35H47N5O4, 602.36; found 
602.27 (100%); Anal. calcd. for C35H47N5O4: C, 69.86; H, 7.87; N, 11.64. Found: C, 69.97; H, 
7.84; N, 11.45. 
4.3. General procedure for the synthesis of the N-Fmoc-protected amines (R)-12a,b and (S)-
12a-c 
Raney Ni (30 mg) and hydrazine monohydrate (0.186 mL, 6 mmol) were added to a 
solution of the corresponding amino nitrile (R)- and (S)-1a-c (0.3 mmol) in MeOH (20 mL) 
and the resulting reaction mixture was refluxed for 5 min. Then, the mixture was filtered 
through celite, this was washed with MeOH (3×75 mL), and the filtrates were evaporated to 
dryness. The respective crude reaction mixture of amines (R)-3a,b and (S)-3a-c impurified 
with 5a-c was dissolved in CH3CN (10 mL) and cooled at 0ºC. Propylene oxide (56 µL, 8 
mmol) and Fmoc-Cl (78 mg, 0.3 mmol) were added. The solution was stirred for 2h. Then, 
the solvent was evaporated and the residue was dissolved in EtOAc (50 mL). This solution 
was successively washed with H2O (20 mL) and brine (20 mL), dried over Na2SO4, and 
evaporated to dryness. The residue was purified by flash chromatography, using 10-40% 
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EtOAc gradient in hexane as eluant to give the corresponding Fmoc-protected amine (R)-
12a,b and (S)-12a-c. 
4.3.1. N-Boc-N-[(2R)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-ornithine benzyl amide [(R)-
12a] 
Foam (112 mg, 55%); HPLC tR 20.56 min; []D
20
 +7.1 (c 1, MeOH); 
1
H NMR (400 MHz, 
CDCl3) δ 1.10-1.98 [m, 4H, β-H and γ-H (Orn)], 1.36 (s, 9H, Boc), 2.76-3.14 [m, 5H, 2-H, 3-
H (Pr) and δ-H (Orn)], 3.24 [m, 1H, α-H (Orn)], 3.26-3.55 [m, 1H, 1-H (Pr)], 4.19 [t, 1H, J=7 
Hz, CH (Fmoc)], 4.37 [d, 2H, J=7 Hz, CH2 (Fmoc)], 4.42 [dd, 2H, J=5 and 15 Hz, CH2 (Bn)], 
4.71 (bs, 1H, NH-Boc), 5.75 (1bs, 1H, NH-Fmoc), 7.14-7.76 (m, 19H, aromatics and NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 26.0(CH2, Cγ), 28.3 (3CH3, Boc), 30.7 (CH2, Cβ), 39.1 (CH2, 
C3), 39.5 (CH2, Cδ), 43.1 (CH2, Bn), 44.6 (CH2, C1), 47.1 (CH, Fmoc), 59.6 (CH, C2), 60.2 
(CH, Cα), 66.5 (CH2, Fmoc), 79.2 (C, Boc), 119.9-143.9 (18CH and 6C, aromatics), 156.2 
(CO, Boc), 156.8 (CO, Fmoc), 174.2 (CONH); ES-MS m/z [M+1]
+
 calcd for C41H48N4O5, 
677.36; found 677.59 (100 %); Anal. calcd. for C41H48N4O5: C, 72.76; H, 7.15; N, 8.28. 
Found: C, 72.93; H, 7.34; N, 8.05. 
4.3.2. N-Boc-N-[(2S)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-ornithine benzyl amide [(S)-
12a] 
Foam (162 mg, 80%); HPLC tR 21.26 min; []D
20
 +15.4 (c 1, MeOH); 
1
H NMR (400 MHz, 
CDCl3) δ 1.41 (s, 9H, Boc), 1.46-1.59 [m, 4H, β-H and γ-H (Orn)], 2.41-2.71 [(m, 2H, 3-H 
(Pr)], 2.77 [m, 1H, 2-H (Pr)] , 2.97-3.16 [m, 2H, δ-H(Orn)], 3.16-3.43 [m, 3H, α-H and 1-H 
(Orn)], 3.83 ]dd, 2H, J=7, 15 Hz, CH2(Bn)], 4.20 [t, 1H, J=6.5 Hz, CH (Fmoc)], 4.35 [dd, 2H, 
J=5, 15 Hz, CH2 (Bn)], 4.42 [d, 2H, J=6.5 Hz, CH2 (Fmoc)], 4.75  (bs, 1H, NH-Boc), 5.32 
(1bs, 1H, NH-Fmoc),  6.91 (1bs, 1H, NH-Bn), 7.04-7.77 (m, 19H, aromatics); 
13
C NMR (100 
MHz, CDCl3) δ 26.3(CH2, Cγ), 28.4 (3CH3, Boc), 30.9 (CH2, Cβ), 39.6 (CH2, C3), 40.1 (CH2, 
Cδ), 42.7 (CH2, Bn), 43.1 (CH2, C1), 47.2 (CH, Fmoc), 58.7 (CH, C2), 59.1 (CH, Cα), 66.7 
(CH2, Fmoc), 79.3 (C, Boc), 119.9-143.8 (18CH and 6C, aromatics), 156.3 (CO, Boc), 157.1 
(CO, Fmoc), 174.2 (CONH); ES-MS m/z [M+1]
+
 calcd for C41H48N4O5, 677.36; found 677.59 
(100 %);  Anal. calcd. for C41H48N4O5: C, 72.76; H, 7.15; N, 8.28. Found: C, 72.89; H, 7.32; 
N, 8.12. 
15 
 
4.3.3. Nε-Boc-N-[(2R)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-lysine benzyl amide [(R)-
12b] 
Foam (132 mg, 64%); HPLC tR 20.68 min; []D
20
 +8.2 (c 0.8, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 0.91-164 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.44 (s, 9H, Boc), 2.48-2.83 [m, 
3H, 2-H (Pr) and ε-H (Lys)], 2.88-3.02 [m, 2H, 3-H (Pr)], 3.06-3.19 [m, 3H, 1-H (Pr) and α-H 
(Lys)], 4.17 [t, 1H, J=7.5 Hz, CH (Fmoc)], 4.28-4.47 [m, 4H, CH2 (Fmoc) and CH2 (Bn)], 
4.60 (bs, 1H, NH-Boc), 5.18 (1bs, 1H, NH-Fmoc), 7.09 (1bs, 1H, NH-Bn),  7.11-7.75 (m, 
19H, aromatics); 
13
C NMR (100 MHz, CDCl3) δ 22.4 (CH2, Cγ), 28.3 (3CH3, Boc), 29.6 
(CH2, Cδ), 33.1 (CH2, Cβ), 38.9 (CH2, C3), 39.9 (CH2, Cε), 42.9 (CH2, Bn), 44.6 (CH2, C1), 
47.1 (CH, Fmoc), 59.2 (CH, C2), 61.1 (CH, Cα), 66.4 (CH2, Fmoc), 78.9 (C, Boc), 119.8-
143.8 (18CH and 6C, aromatics), 155.9 (CO, Boc), 156.7 (NHCOO, Fmoc), 174.4 (CONH); 
ES-MS m/z [M+1]
+
 calcd for C42H50N4O5, 691.38; found  691.59 (100 %); Anal. calcd. for 
C42H50N4O5: C, 73.02; H, 7.29; N, 8.11. Found: C, 72.89; H, 7.32; N, 8.02. 
4.3.4. Nε-Boc-N-[(2S)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-lysine benzyl amide [(S)-
12b] 
Foam (145 mg, 70%); HPLC tR 21.21 min; []D
20
 +12.3 (c 0.9, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 1.16-1.86 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.42 (s, 9H, Boc), 2.42-2.68 [m, 
2H, 3-H (Pr)], 2.72 [m, 1H, 2-H (Pr)], 2.88-3.44 [m, 4H, 1-H (Pr) and ε-H(Lys)], 3.22 [m, 1H, 
α-H (Lys)], 3.83 [dd, 1H, J= 7 and 15 Hz, CH2 (Bn)], 4.19 [t, 1H, J=7.5 Hz, CH (Fmoc)], 
4.35 [dd, 1H, J= 7, 15 Hz, CH2 (Bn)], 4.41 [d, 2H, J=7.5 Hz, CH2 (Fmoc)], 4.57 (bs, 1H, NH-
Boc), 5.19 (1bs, 1H, NH-Fmoc), 7.04 (1bs, 1H, NH-Bn),  7.07-7.77 (m, 19H, aromatics); 
13
C 
NMR (100 MHz, CDCl3) δ 22.5(CH2, Cγ), 28.4 (3CH3, Boc), 29.8 (CH2, Cδ), 33.5 (CH2, Cβ), 
39.8 (CH2, C3), 41.5 (CH2, Cε), 42.7 (CH2, Bn), 43.5 (CH2, C1), 47.2 (CH, Fmoc), 59.3 (CH, 
C2), 60.2 (CH, Cα), 66.7 (CH2, Fmoc), 79.1 (C, Boc), 119.9-143.7 (18CH and 6C, aromatics), 
156.2 (CO, Boc), 157.0 (CO, Fmoc), 174.4 (CONH); ES-MS m/z [M+1]
+
 calcd for 
C42H50N4O5, 691.38; found  691.59 (100 %) [M+1]
+
; Anal. calcd. for C42H50N4O5: C, 73.02; 
H, 7.29; N, 8.11. Found: C, 73.14; H, 7.38; N, 7.96. 
4.3.5. N-Pbf-N-[(2S)-3-Phenyl-1-(Fmoc)amino-propan-2-yl)-arginine benzyl amide [(S)-
12c] 
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Foam (222 mg, 85 %); HPLC [Sunfire C18, 3.9×50 mm, 3.5 m, (10-100 %, 5 min) 
gradient of solvent A in solvent B] tR 4.65 min; [α]D
20
 +6.4 (c 1, MeOH); 
1
H-RMN (500 
MHz,CDCl3) δ (ppm): 1.12-1.80 [m, 4H, β-H and γ-H (Arg)], 1.45 [s, 6H, 2 CH3 (Pbf)], 2.09 
[s, 3H, CH3 (Pbf)], 2.51 [s, 3H, CH3 (Pbf)], 2.59 [s, 3H, CH3 (Pbf)], 2.66-2.84 [m, 2H, 1-H 
(Pr)]), 2.73 [m, 1H, 2-H (Pr)], 2.92 [s, 2H, CH2 (Pbf)], 3.02-3.55 [m, 4H, 1-H (Pr) and δ-
H(Arg)], 3.38 [m, 1H, α-H (Arg)], 3.85 [dd, 1H, J = 7.5 and 15 Hz, CH2 (Bn)], 4.17 [t, 1H, J = 
7 Hz, CH2 (Fmoc)], 4.29 [dd, 1H, J = 7.5 and 15 Hz, CH2 (Bn)], 4.25-4.53 [m, 2H, CH2 
(Fmoc)], 5.60 (bs, 1H, NH-Fmoc), 6.28 (bs, 3H, guanidine NH), 6.97-7.78 (m, 15H, 
aromatics); 
13
C-RMN (125 MHz, CDCl3) δ (ppm): 12.9, 18.3, 19.7, 28.9 (5CH3, Pbf), 25.7 
(CH2, Cγ), 30.1 (CH2, Cβ), 31.3 (CH2, C3), 40.3 (CH2, Cδ), 43.1 (CH2, C1), 43.6 (CH2, Pbf), 
47.6 (CH, Fmoc), 59.2 (CH, C2), 59.5 (CH,  Cα), 67.1 (CH2, Fmoc), 86.77, 117.93, 125.0, 
132.6, 133.3 (5C, Pbf), 126.9-139.2 (15CH and 5C, aromatics and Pbf), 156.7 ( CO, Fmoc), 
157.7-159.2 (C=NH, guanidine), 174.8 (CONH); ES-MS m/z [M+1]
+
 calcd for C50H58N6O6S: 
871.77; found 871.77 (100%); Anal. calcd. for C50H58N6O6S: C, 68.94; H, 6.71; N, 9.65. 
Found: C, 69.07; H, 6.82; N, 9.46. 
4.4. General procedure for the synthesis of basic amino acid-derived ureas. Method B. 
Synthesis of ureas (R)-8a,b, (S)-8a-c, (R)- and (S)-13a, and (R)- and (S)-14-16b 
Diethyl amine (0.32 mL, 3 mmol) was added to a solution of the corresponding Fmoc-
protected amine 12a-c (0.3 mmol) and the reaction mixture was stirred at rt for 2 h. Then, the 
solvent was evaporated to dryness and the residue was dissolved in EtOAc (50 mL). The 
solution was successively washed with H2O (20 mL) and brine (20 mL), dried over Na2SO4, 
and evaporated to dryness. The residue was dissolved in dry CH2Cl2 (10 mL), cooled at 0ºC. 
The corresponding isocyanate (0,3 mmol) was added to this solution and the mixture was 
stirred for15min-2 h. Then, the solvent was evaporated and the residue was dissolved in 
EtOAc (50 mL). This solution was successively washed with H2O (20 mL) and brine (20 
mL), dried over Na2SO4, and evaporated to dryness. The residue was purified by flash 
chromatography, using 20-100% gradient of EtOAc in hexane as eluant to give the 
corresponding urea (R)-8a,b, (S)-8a-c, (R)- and (S)-13a, and (R)- and (S)-14-16b. 
4.4.1. N-Boc-N-[(2R)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-ornithine benzyl amide 
[(R)-8a] 
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Foam (53 mg, 31 %); HPLC tR 17.45 min; [α]D
20
 + 7.2 (c 1, MeOH); 
1
H NMR (400 MHz, 
CDCl3) δ  1.10-2.41 [m, 4H, β-H and γ-H (Orn)], 1.40 (s, 9H, Boc), 2.58-2.76 [m, 2H, 3-H 
(Pr)], 2.81 [m, 1H, 2-H (Pr)], 2.84-3.02 [m, 5H, 1-H (Pr), α-H and δ-H(Orn)], 4.29 [dd, 1H, 
J= 6 and 15 Hz, CH2 (Bn)], 4.41[ dd, 1H, J=6 and 15 Hz, CH2 (Bn)], 4.62 (bs, 1H, NH-Boc), 
6.89-7.42 (m, 16H, aromatics and NH-Bn), 5.77 and 7.57 (2bs, 2H, NHC ONH); 
13
C NMR 
(100 MHz, CDCl3) δ 26.0 (CH2, Cγ), 28.4 (3CH3, Boc), 30.7 (CH2, Cβ), 39.2 (CH2, Cδ), 39.4 
(CH2, C3), 43.2 (CH2, Bn), 43.9 (CH2, C1), 60.2 (CH, Cα), 60.4 (CH, C2), 79.4 (C, Boc), 
119.5-139.2 (15CH and 3 C, aromatics), 156.2 (HNCONH), 156.4 (CO, Boc), 175.0 (CONH);  
ES-MS m/z [M+1]
+
 calcd for C33H43N5O4, 574.33; found  574.27 (100%); Anal. calcd. for 
C33H43N5O4: C, 69.08; H, 7.55; N, 12.21. Found: C, 69.13; H, 7.62; N, 12.08. 
4.4.2. N-Boc-N-[(2S)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-ornithine benzyl amide 
[(S)-8a] 
Foam (144 mg, 84 %); HPLC tR  18.15 min; [α]D
20
 + 6.7 (c 1.1, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 1.10-1.74 [m, 4H, β-H and γ-H (Orn)], 1.42 (s, 9H, Boc), 2.40-2.75 [m, 2H, 
3-H (Pr)], 2.81-3.14 [m, 2H, 1-H (Pr)], 2.93 [m, 1H, 2-H (Pr)], 3.14- 3.48 [m, 3H, α-H and δ-
H (Orn)], 3.70 [dd, 1H, J=7 and 15Hz, CH2 (Bn)], 4.20 (dd, 1H, J=5 and 15Hz, CH2 (Bn)], 
4.94 (bs, 1H, NH-Boc), 6.86-7.47 (m, 15H, aromatics), 6.04 and 8.62 (2bs, 2H, NHCONH), 
7.75 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 26.2 (CH2, Cγ), 28.7 (3CH3, Boc), 30.8 
(CH2, Cβ), 40.2 (CH2, Cδ), 40.6 (CH2, C3), 42.4 (CH2, Bn), 42.9 (CH2, C1), 59.5 (CH, C2), 
59.6 (CH, Cα), 79.9 (C, Boc), 119.6-139.6 (15CH and 3C, aromatics), 156.8 (HNCONH), 
156.9 (CO, Boc), 174.7 (CONH); ES-MS m/z [M+1]
+
 calcd for C33H43N5O4, 574.33; found 
574,52 (100 %), 699.43 (10%) [M+Na]
 +
; Anal. calcd. for C33H43N5O4: C, 69.08; H, 7.55; N, 
12.21. Found: C, 69.17; H, 7.60; N, 12.13. 
4.4.3. Nε-Boc-N-[(2R)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-lysine benzyl amide [(R)-
8b] 
Foam (121 mg, 69%); HPLC tR 18.29 min; [α]D
20 
+6.5 (c 0.6, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 0.73-1.65 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.37 (s, 9H, Boc), 2.53-2.87 [m, 
3H, 3-H and 2-H (Pr)], 2.89-3.00 [m, 2H, 1-H (Pr)], 3.01-3.42 [m, 3H, α-H and ε-H (Lys)], 
4.29 [dd, 1H, J= 6 and 15 Hz, CH2 (Bn)], 4.39 [dd, , 1H, J= 6 and 15 Hz, CH2 (Bn)], 4.59 (s, 
1H, NH-Boc), 5.51 (bs, 1H, HNCONH), 6.87-7.34 (m, 16H, aromatics and HNCONH), 7.56 
(bs, 1H, NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 22.6 (CH2, Cγ), 28.4 (3CH3, Boc), 29.6 
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(CH2, Cδ), 33.3 (CH2, Cβ), 39.0 (CH2, C3), 39.9 (CH2, Cε), 43.1 (CH2, Bn), 43.8 (CH2, C1), 
59.1 (CH, C2), (61.0 (CH, Cα), 79.3 (C, Boc), 122.8-138.4 (15CH and 3C, aromatics), 156.0 
(HNCONH), 156.2 (CO, Boc), 174.0 (CONH); ES-MS m/z [M+1]
+
 calcd for C34H45N5O4, 
588.35; found 588.62 (100%); Anal. calcd. for C34H45N5O4: C, 69.48; H, 7.72; N, 11.92. 
Found: C, 69.62; H, 7.89; N, 12.75. 
4.4.4. Nε-Boc-N-[(2S)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-lysine benzyl amide [(S)-
8b] 
Foam (143 mg, 81%); HPLC tR 18.49 min; [α]D
20
 + 4.0 (c 0.9, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 1.00-1.90 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.46 (s, 9H, Boc), 2.51-2.68 [m, 
2H, 3-H (Pr)], 2.73 [m, 1H, 2-H (Pr)], 2.90-3.18 [m, 2H, ε-H (Lys)], 3.18-3.50 [m, 3H, 1-H 
(Pr) and α-H (Lys)], 3.90 [dd, 1H, J=7 and 15Hz, CH2 (Bn)], 4.35 [dd, 1H, J=4 and 15Hz, 
CH2 (Bn)], 4.88 (bs, 1H, NH-Boc), 6.82-7.20 (m,16H, aromatics and NH-Bn), 5.98 and 8.09 
(2bs, 2H, HNCONH); 
13
C NMR (100 MHz, CDCl3) δ  21.1 (CH2, Cγ), 26.3 (3CH3, Boc), 27.6 
(CH2, Cδ), 27.9 (CH2, Cβ), 30.9 (CH2, C3), 38.1 (CH2, Cε), 39.8 (CH2, C1), 40.7 (CH2, Bn), 
58.0 (CH, C2), 58.4 (CH, Cα), 77.4 (C, Boc), 117.0-137.3 (15CH and 3 C, aromatics), 154.7 
(CO, Boc), 154.8 (HNCONH), 172.1 (CONH); ES-MS m/z [M+1]
+
 calcd for C34H45N5O4, 
588.35; found, 588.55 (100 %); Anal. calcd. for C34H45N5O4: C, 69.48; H, 7.72; N, 11.92. 
Found: C, 69.59; H, 7.84; N, 12.85. 
4.4.5. Nε-Pbf-N-[(2S)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-arginine benzyl amide 
[(S)-8c] 
Foam ( 68 mg, 29 %); HPLC tR 19.95 min; [α]D
20
 +2.5 (c 1, MeOH); 
1
H-NMR (500 MHz, 
CDCl3) δ  0.61-1.63 [m, 4H, β- and γ-H (Arg)], 1.38, 2.01, 2.39 and 2.45 [4s, 15H, CH3 
(Pbf)], 2.74 [m, 1H, 2-H (Pr)], 2.85 [s, 2H, CH2 (Pbf)], 2.92-3.17 [m, 4H, 3-H (Pr) and δ-
H(Arg)], 3.20-3.42 [m, 2H, 1-H (Pr)], 3.99 [bs, 1H, α-H (Arg)], 4.17 [d, 1H, J = 6 and 14.5 
Hz, CH2 (Bn)], 4.30 [dd, 1H, J = 4.5 and 14.5 Hz, CH2 (Bn)], 6.20 [bs, 3H, guanidino], 6.85 (t, 
1H, J = 6 Hz, NH-Bn), 7.00-7.34 (m, 15H, aromatics), 7.78 and 8.15 (2bs, 2H, NHCONH); 
13
C-NMR (125 MHz, CDCl3) δ 12.9, 18.3, 19.7, 28.9 (CH3, Pbf), 25.7 (CH2, Cγ), 30.1 (CH2, 
Cβ), 31.3 (CH2, C3), 40.3 (CH2, Cδ), 43.6 (CH2, C1), 43.6 (CH2, Pbf), 59.2 (CH, C2), 59.5 (CH,  
Cα), 86.77, 117.93, 125.0, 132.6, 133.3 (5 C, Pbf), 126.9-139.2 [15 CH and 4C, aromatics and 
Pbf], 156.4 (HNCONH), 159.2 (guanidino); ES-MS m/z [M+1]
+
 calcd. for C42H53N7O5S, 
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767.38; found, 768.81 (100%). Anal. calcd. for C42H53N7O5S: C, 65.69; H, 6.96; N, 12.77; 
Found: C, 65.82; H, 7.04; N, 12.68. 
4.4.6. N-Boc-N-[(2R)-1-(3-Benzylureido)-3-phenylpropan-2-yl]-ornithine benzyl amide 
[(R)-13a] 
Foam (80 mg, 45 %); HPLC tR 18.47 min; [α]D
20
 +6.5 (c 1.1, MeOH); 
1
H NMR (500 MHz, 
CDCl3) δ  1.19-1.69 [m, 4H, β-H and γ-H (Orn)], 1.39 (s, 9H, Boc), 2.61-2.65 [m, 2H, 3-H 
(Pr)], 2.80 [m, 1H, 2-H (Pr)], 2.87-3.20 [m, 4H, 1-H (Pr), and δ-H(Orn)], 3.21 [m,1H, α-H 
(Orn)], 4.27 [m, 2H, CH2 (Bn-ureido)], 4.32 [dd, 1H, J= 6 and 15 Hz, CH2 (Bn)], 4.40 [ dd, 
1H, J=6 and 15 Hz, CH2 (Bn)], 4.58 (bs, 1H, NH-Boc), 4.73 and 5.06 (2bs, 2H, NHCONH), 
7.07-7.36 (m, 16H, aromatics and NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 26.1 (CH2, Cγ), 
28.4 (3CH3, Boc), 30.6 (CH2, Cβ), 39.4 (CH2, C3), 39.5 (CH2, Cδ), 43.2 (CH2, Bn), 43.9 [CH2, 
(Bn-ureido)], 44.4 (CH2, C1), 59.4 (CH, C2), 59.9 (CH, Cα), 79.4 (C, Boc), 127.2-138.7 
(15CH and 3 C, aromatics), 156.2 (CO, Boc), 158.2  (HNCONH), 174.6 (CONH);  ES-MS 
m/z [M+1]
+
 calcd for C34H45N5O4, 588.35; found  588.48 (100%); Anal. calcd. for 
C34H45N5O4: C, 69.48; H, 7.72; N, 11.92. Found: C, 69.61; H, 7.62; N, 12.08. 
4.4.7. N-Boc-N-[(2S)-1-(3-Benzylureido)-3-phenylpropan-2-yl]-ornithine benzyl amide 
[(S)-13a] 
Foam (112 mg, 64 %); HPLC tR  18.86 min; [α]D
20
 + 7.0 (c 0.9, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 1.31 (s, 9H, Boc), 1.41-1.85 [m, 4H, β-H and γ-H (Orn)], 2.45-2.81 [m, 2H, 
3-H (Pr)], 2.74 [m, 1H, 2-H (Pr)], 2.86-3.34  [m, 4H, 1-H (Pr) and δ-H (Orn)], 3.42 [m, 2H,  
α-H (Orn)], 3.78 [dd, 1H, J=7 and 15Hz, CH2 (Bn)], 4.30 (dd, 1H, J=4 and 15Hz, CH2 (Bn)], 
4.37 [m, 2H, CH2 (Bn-ureido)], 4.94 (bs, 1H, NH-Boc), 6.86-7.47 (m, 15H, aromatics), 5.81 
(1bs, 2H, NHCONH),  6.96 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 25.8  (CH2, Cγ), 
28.3 (3CH3, Boc), 30.5 (CH2, Cβ), 39.8 (CH2, Cδ), 40.3 (CH2, C3), 41.7 (CH2, Bn), 42.6 [CH2, 
(Bn-ureido)], 44.3 (CH2, C1), 58.6 (CH, C2), 59.2 (CH, Cα), 79.7 (C, Boc), 126.3-139.7 
(15CH and 3C, aromatics), 156.7 (CO, Boc), 159.2 (HNCONH), 174.4 (CONH); ES-MS m/z 
[M+1]
+
 calcd for C34H45N5O4, 588.35; found  588.62 (100%); Anal. calcd. for C34H45N5O4: C, 
69.48; H, 7.72; N, 11.92. Found: C, 69.63; H, 7.84; N, 11.87. 
4.4.8.   Nε-Boc-N-[(2R)-1-(3-(2,4-Dichlorophenyl)ureido)-3-phenylpropan-2-yl]-lysine 
benzyl amide [(R)-14b] 
20 
 
Foam (125 mg, 63%); HPLC tR 20.05 min; [α]D
20 
+7.5 (c 1, MeOH); 
1
H NMR (400 MHz, 
CDCl3) δ 0.73-1.65 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.42 (s, 9H, Boc), 2.63 [dd, 1H, J= 6 
and 13.5 Hz, 3-H (Pr)], 2.72 [dd, 1H, J= 6 and 13.5 Hz, 3-H (Pr)], 2.83-3.14 [m, 5H, 1-H (Pr), 
2-H (Pr), and ε-H (Lys)], 3.32 [m, 1H, α-H (Lys)], 4.30 [dd, 1H, J= 6 and 15 Hz, CH2 (Bn)], 
4.40 [dd, , 1H, J= 6 and 15 Hz, CH2 (Bn)], 4.55 (s, 1H, NH-Boc), 5.96 (bs, 2H, HNCONH), 
7.04-7.31 (m, 13H, aromatics), 7.33 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, CDCl3) δ 22.5 
(CH2, Cγ), 28.4 (3CH3, Boc), 29.6 (CH2, Cδ), 33.6 (CH2, Cβ), 39.2 (CH2, C3), 39.8 (CH2, Cε), 
43.2 (CH2, Bn), 43.9 (CH2, C1), 58.9 (CH, C2), 60.8 (CH, Cα), 79.4 (C, Boc), 121.5-138.2 
(13CH and 5C, aromatics), 154.9 (HNCONH), 156.3 (CO, Boc), 175.0 (CONH); ES-MS m/z 
[M+1]
+
 calcd for C34H43Cl2N5O4, 656.27; found, 656.66 (100%), 658.62 (70%) [M+3]
+
, 
660.65 (10%) [M+5]
+
; Anal. calcd. for C34H43Cl2N5O4: C, 62.19; H, 6.60; N, 10.67. Found: 
C, 62.32; H, 6.75; N, 10.48. 
4.4.9.   Nε-Boc-N-[(2S)-1-(3-(2,4-Dichlorophenyl)ureido)-3-phenylpropan-2-yl]-lysine 
benzyl amide [(S)-14b] 
Foam (147 mg, 74%); HPLC tR 20.03 min; [α]D
20 
+3.0 (c 0.8, MeOH); 
1
H NMR (300 
MHz, CDCl3) δ 0.86-2.19 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.45 (s, 9H, Boc), 2.66-2.91 [m, 
3H, 2-H and 3-H (Pr)], 3.00-3.54 [m, 5H, 1-H (Pr), α-H and ε-H (Lys)], 4.00 [dd, 1H, J= 6.5 
and 15 Hz, CH2 (Bn)], 4.37 [dd, , 1H, J= 6.5 and 15 Hz, CH2 (Bn)], 4.86 (s, 1H, NH-Boc), 
6.33 (bs, 2H, HNCONH), 6.90-7.58 (m, 13H, aromatics), 7.70 (bs, 1H, NH-Bn); 
13
C NMR 
(100 MHz, CDCl3) δ 20.8 (CH2, Cγ), 28.5 (3CH3, Boc), 29.7 (CH2, Cβ and Cδ), 36.6  (CH2, 
C3), 39.7 (CH2, Cε), 40.0 (CH2, Bn), 42.9 (CH2, C1), 60.2 (CH, C2), 60.4 (CH, Cα), 79.9 (C, 
Boc), 121.4-138.5 (13CH and 5C, aromatics), 154.7 (CO, Boc),157.2  (HNCONH), 170.2 
(CONH); ES-MS m/z [M+1]
+
 calcd for C34H43Cl2N5O4, 656.27; found, 656.46 (100%), 
658.48 (80%) [M+3]
+
, 660.49 (15%) [M+5]
+
; Anal. calcd. for C34H43Cl2N5O4: C, 62.19; H, 
6.60; N, 10.67. Found: C, 62.29; H, 6.71; N, 10.55. 
4.4.10.   Nε-Boc-N-[(2R)-1-(3-(4-Methoxyphenethyl)ureido)-3-phenylpropan-2-yl]-lysine 
benzyl amide [(R)-15b] 
Foam (127 mg, 66%); HPLC tR 18.29 min; [α]D
20 
+8.5 (c 1.1, MeOH); 
1
H NMR (400 
MHz, CDCl3) δ 0.78-1.71 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.42 (s, 9H, Boc), 2.66 [t, 2H, J= 
7 Hz, 2-H (ethyl)], 2.66-2.82 [m, 3H, 2-H and 3-H (Pr)], 2.91-3-18 [m, 5H, 1-H (Pr), α-H and 
ε-H (Lys)], 3.28 [dd, 2H, J= 7 and 13 Hz, 1-H (ethyl)], 3.76 (s, 3H, OMe), 4.32 [dd, 1H, J= 6 
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and 14.5 Hz, CH2 (Bn)], 4.41 [dd, , 1H, J= 6 and 14.5 Hz, CH2 (Bn)], 4.55 (bs, 1H, NH-Boc), 
4.70 (bs, 2H, HNCONH), 7.04-7.33 (m, 14H, aromatics), 7.57 (bs, 1H, NH-Bn); 
13
C NMR 
(100 MHz, CDCl3) δ 22.6 (CH2, Cγ), 28.4 (3CH3, Boc), 29.7 (CH2, Cδ), 30.0 (CH2, Cβ), 35.4 
(CH2, C3), 35.5 [CH2, C2 (ethyl)], 38.9 [CH2, Cε and C1 (ethyl)], 43.1 (CH2, Bn), 43.9 (CH2, 
C1), 55.2 (CH3, OMe), 59.5 (CH, C2), 60.9 (CH, Cα), 79.1 (C, Boc), 113.9-138.5 (14CH and 
4C, aromatics), 156.0 (CO, Boc), 158.3 (HNCONH), 174.6 (CONH); ES-MS m/z [M+1]
+
 
calcd for C37H51N5O5, 646.39; found, 646.72 (100 %); Anal. calcd. for C37H51N5O5: C, 68.81; 
H, 7.96; N, 10.84. Found: C, 68.96; H, 8.07; N, 10.48. 
4.4.11.   Nε-Boc-N-[(2S)-1-(3-(4-Methoxyphenethyl)ureido)-3-phenylpropan-2-yl]-lysine 
benzyl amide [(S)-15b] 
Foam (143 mg, 87%); HPLC tR 18.43 min; [α]D
20 
+5.9 (c 1, MeOH); 
1
H NMR (300 MHz, 
CDCl3) δ 1.09-2.23 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.43 (s, 9H, Boc), 2.60-2.69 [m, 2H, 3-
H (Pr)], 2.65-2.72 [m, 2H, 2-H (Pr)], 2.76 [t, 2H, J= 7 Hz, 2-H (ethyl)],  2.99-3-17 [m, 4H, 1-
H (Pr) and ε-H (Lys)], 3.29-3.50 [m, 1H, -H (Lys)], 3.40 [dd, 2H, J= 7 and 13 Hz, 1-H 
(ethyl)], 3.80 (s, 3H, OMe), 3.91 [dd, 1H, J= 7 and 15 Hz, CH2 (Bn)], 4.35 [dd, , 1H, J= 7 and 
15 Hz, CH2 (Bn)], 4.85 (bs, 1H, NH-Boc), 5.15 and 5.29 (2bs, 2H, HNCONH), 6.75-7.44 (m, 
15H, aromatics and NH-Bn); 
13
C NMR (75 MHz, CDCl3) δ 23.6 (CH2, Cγ), 28.8 (3CH3, Boc), 
30.1 (CH2, Cδ), 30.5 (CH2, Cβ), 33.5 (CH2, C3), 35.5 [CH2, C2 (ethyl)], 40.5 (CH2, Cε), 40.8 
[CH2, C1 (ethyl)], 42.2 (CH2, Bn), 43.1 (CH2, C1), 55.6 (CH3, OMe), 60.6 (CH, C2), 60.8 (CH, 
Cα), 79.9 (C, Boc), 114.3-139.5 (14CH and 4C, aromatics), 157.1 (CO, Boc), 159.5 
(HNCONH), 174.9 (CONH); ES-MS m/z [M+1]
+
 calcd for C37H51N5O5, 646.39; found, 
646.52 (100 %); Anal. calcd. for C37H51N5O5: C, 68.81; H, 7.96; N, 10.84. Found: C, 68.93; 
H, 8.01; N, 10.69. 
4.4.12.   Nε-Boc-N-[(2R)-1-(3-(4-Fluorophenethyl)ureido)-3-phenyl)propan-2-yl]-lysine 
benzyl amide [(R)-16b] 
Foam (118 mg, 63%); HPLC tR 18.47 min; [α]D
20 
+7.6 (c 1, MeOH); 
1
H NMR (300 MHz, 
CDCl3) δ 0.81-2.11 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.46 (s, 9H, Boc), 2.56-2.89 [m, 3H, 2-
H and 3-H (Pr)], 2.77 [t, 2H, J= 7 Hz, 2-H (ethyl)], 2.93-3.28 [m, 5H, 1-H (Pr), α-H and ε-H 
(Lys)], 3.32 [dd, 2H, J= 7 and 13 Hz, 1-H (ethyl)], 4.41 [d, 2H, J= 7 Hz, CH2 (Bn)], 4.58 (bs, 
1H, NH-Boc), 4.80 (bs, 2H, HNCONH), 6.89-7.48 (m, 14H, aromatics), 7.52 (bs, 1H, NH-
Bn); 
13
C NMR (75 MHz, CDCl3) δ 22.3 (CH2, Cγ), 28.0 (3CH3, Boc), 29.3 (CH2, Cδ), 30.5 
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(CH2, Cβ), 32.9 [CH2, C2 (ethyl)], 35.2 (CH2, C3), 38.9 (CH2, Cε), 41.2 [CH2, C1 (ethyl)], 42.7 
(CH2, Bn), 43.8 (CH2, C1), 59.1 (CH, C2), 60.7 (CH, Cα), 79.8 (C, Boc), 114.7-159.5 (14CH 
and 4C, aromatics), 155.7 (CO, Boc), 157.9 (HNCONH), 174.4 (CONH); ES-MS m/z [M+1]
+
 
calcd for C36H48FN5O4, 634.37; found, 634.68 (100 %); Anal. calcd. for C36H48FN5O4: C, 
68.22; H, 7.63; N, 11.05. Found: C, 68.38; H, 7.75; N, 10.89. 
4.4.13.   Nε-Boc-N-[(2S)-1-(3-(4-Fluorophenethyl)ureido)-3-phenyl)propan-2-yl]-lysine 
benzyl amide [(S)-16b] 
Foam (168 mg, 89%); HPLC tR 18.57 min; [α]D
20 
+3.5 (c 1.1, MeOH); 
1
H NMR (300 
MHz, CDCl3) δ 0.77-2.23 [m, 6H, β-H, γ-H and δ-H (Lys)], 1.45 (s, 9H, Boc), 2.58-2.73 [m, 
3H, 2-H and 3-H (Pr)], 2.73 [t, 2H, J= 7 Hz, 2-H (ethyl)], 2.94-3.28 [m, 4H, 1-H (Pr) and ε-H 
(Lys)], 3.28-3.37 [m, 1H, -H (Lys)], 3.40 [dd, 2H, J= 7 and 13 Hz, 1-H (ethyl)], 3.89 [dd, J= 
7 and 15 Hz, CH2 (Bn)], 4.34 [dd, J= 7 and 15 Hz, CH2 (Bn)], 4.88 (bs, 1H, NH-Boc), 5.26 
and 5.41 (2bs, 2H, HNCONH), 6.88-7.60 (m, 15H, aromatics and NH-Bn); 
13
C NMR (75 
MHz, CDCl3) δ 23.6 (CH2, Cγ), 28.8 (3CH3, Boc), 30.1 (CH2, Cδ), 30.5 (CH2, Cβ), 33.6 [CH2, 
C2 (ethyl)], 36.2 (CH2, C3), 40.5 (CH2, Cε), 40.9 [CH2, C1 (ethyl)], 42.0 (CH2, Bn), 43.1 (CH2, 
C1), 60.6 (CH, C2), 60.8 (CH, Cα), 79.8 (C, Boc), 115.5-139.6 (14CH and 4C, aromatics), 
157.1 (CO, Boc), 160.3 (HNCONH), 175.0 (CONH); ES-MS m/z [M+1]
+
 calcd for 
C36H48FN5O4, 634.37; found, 634.43 (100 %); Anal. calcd. for C36H48FN5O4: C, 68.22; H, 
7.63; N, 11.05. Found: C, 68.36; H, 7.78; N, 10.95. 
4.5. General procedure for the N-Boc-deprotection of protected ureas (RS)-9b, (R)- and (S)-
8a,b, (R)-, (S)-9a and -13a, (R)- and (S)-14-16b. Synthesis of urea hydrochlorides (R)- 
and (S)-11a, (RS)-11b, (R)- and (S)-17a,b, (R)- and (S)-18a, (R)- and (S)-19-21b 
The corresponding protected urea (0.10 mmol) was dissolved in a 3M solution of  HCl in 
EtOAc (2 mL) and stirred at rt for 2 h. Then, the solvent was evaporated under reduced 
pressure, the residue was dissolved in H2O (3 mL) and the solution was lyophilized. 
4.5.1. N-[(2R)-4-Phenyl-1-(3-phenylureido)butan-2-yl]-ornithine benzyl amide 
dihydrochloride [(R)-11a] 
Amorphous solid (56 mg, 100 %); []D
20
 + 6.9 (c 0.9, MeOH); 
1
H NMR (400 MHz, 
DMSO-d6) δ 1.51-2.06 [m, 6H, 3-H (Bu), - and β-H (Orn)], 2.64-2.94 [m, 4H, 4-H (Bu) and 
-H (Orn)], 3.08 [m, 1H, 2-H (Bu)], 3.22-3.45 [m, 2H, 1-H (Bu)], 4.09 [m, 1H, -H (Orn)], 
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4.25 [dd, 1H, J = 5 and 15 Hz, CH2 (Bn)], 4.40 [dd, 1H, J = 4 and 15 Hz, CH2 (Bn)], 6.74 and 
6.91 (2 bs, 2H, HNCONH), 6.97-7.47 (m, 15H, Ph), 7.95 [bs, 3H, -NH3
+
 (Orn)], 9.11 and 
9.43 [2bs, 2H, -NH2
+ 
(Orn)], 9.33 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.7  
(CH2, C), 27.2 (CH2, Cβ), 28.1 (CH2, C4), 29.4 (CH2, C3), 31.0 (CH2, C), 38.1 [CH2, (Bn)], 
42.6 (CH2, C1), 56.6 (CH, C2), 57.8 (CH, C), 118.7-140.7 (15CH, and 3C, Ph), 156.5 
(HNCONH), 166.9 (CONH); ES-MS m/z [M+1]
+
 calcd. for C29H37N5O2, 488.29; found, 
488.50 (100%). 
4.5.2. N-[(2S)-4-Phenyl-1-(3-phenylureido)butan-2-yl]-ornithine benzyl amide 
dihydrochloride [(S)-11a] 
Amorphous solid (55 mg, 100 %); []D
20
 + 11.3 (c 1, MeOH); 
1
H NMR (400 MHz, 
DMSO-d6) δ 1.61-2.09 [m, 6H, 3-H (Bu), - and β-H (Orn)], 2.55-2.96 [m, 4H, 4-H (Bu) and 
-H (Orn)], 3.05 [m, 1H, 2-H (Bu)], 3.35-3.71 [m, 2H, 1-H (Bu)], 4.25 [m, 1H, -H (Orn)], 
4.33 [d, 2H, J = 5, CH2 (Bn)], 6.92 and 7.32  (2 bs, 2H, HNCONH), 7.12-7.64 (m, 15H, Ph), 
8.07 [bs, 3H, -NH3
+
 (Orn)], 9.11 and 9.43 [2bs, 2H, -NH2
+ 
(Orn)], 9.19 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.4  (CH2, C), 27.1 (2CH2, C4 and Cβ), 30.5 (CH2, C3), 
30.9 (CH2, C), 37.8 [CH2, (Bn)], 42.4 (CH2, C1), 57.2 (CH, C2), 57.5 (CH, C), 117.7-139.9 
(15CH, and 3C, Ph), 156.0 (HNCONH), 166.5 (CONH); ES-MS m/z [M+1]
+
 calcd. for 
C29H37N5O2, 488.29; found, 488.50 (100%). 
4.5.3. N-[4-Phenyl-1-(3-phenylureido)butan-2-yl]-lysine benzyl amide dihydrochloride 
[(RS)-11b] 
Amorphous solid (57 mg, 29 %); HPLC tR 13.26 [(R)-9b] and 13.45 min [(S)-9b]; 
1
H 
NMR (400 MHz, DMSO-d6) δ 1.23-1.40 [m, 2H, -H (Lys)], 1.43-1.62 [m, 2H, β-H (Lys)], 
1.70-1,96 [m, 4H, -H (Lys) and 3-H (Bu)], 2.58-2.78 [m, 4H, 4-H (Bu) and ε-H (Lys)], 2.91-
3.06 [m, 1H, 2-H (Bu)], and -H (Lys)], 3.38-3.65 [m, 2H, 1-H (Bu)], 4.03 and 4.16 [2m, 1H, 
-H (Lys)], 4.26 [dd, 0.5H, J= 7 and 15 Hz, CH2 (Bn)], 4.30 [d, 1H, J = 5 Hz, CH2 (Bn)], 4.35 
[dd, 0.5H, J= 7 and 15 Hz, CH2 (Bn)], 6.77 (bs, 2H, HNCONH), 7.10-7.43 (m, 15 H, Ph), 
7.92 [bs, 3H, -NH3
+
 (Lys)], 8.93, 8.77, 9.33 and 9.46 [4bs, 2H, -NH2
+ 
(Lys)], 9.32 (bs, 1H, 
NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.9 (CH2, C), 29.8 (CH2, C), 32.1 (CH2, C4), 
33.0 (CH2, Cβ), 34.8 (CH2, C3), 40.0 (CH2, Cε), 42.0 and 43.0 (CH2, C1), 43.3 [CH2, (Bn)], 
56.9 and 58.8 (CH, C2), 60.1 (CH, C), 119.1-141.3 (15CH, and 3C, Ph), 156.2 and 156.7 
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(HNCONH), 174.9  (CONH); ES-MS m/z [M+1]
+
 calcd. for C30H39N5O2, 502.31; found, 
502.50 (100%). 
4.5.4. N-[(2R)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-ornithine benzyl amide 
dihydrochloride [(R)-17a] 
Amorphous solid (54 mg, 100 %); HPLC tR 12.87 min; [α]D
20
 + 5.5 (c 1.3, MeOH);  
1
H 
NMR (400 MHz, DMSO-d6) δ 1.56-1.79 [m, 2H, γ-H (Orn)], 1.80-2.07 [m, 2H, β-H (Orn)], 
2.69-3.31 [m, 7H, 1-H, 2-H, 3-H (Pr) and δ-H(Orn)], 4.25 [dd, 1H, J= 6 and 15 Hz, CH2 
(Bn)], 4.33 [m, 2H, α-H (Orn)], 4.50 [dd, 1H, J=6 and 15 Hz, CH2 (Bn)], 6.89 (bs, 2H, 
NHCONH), 6.79-7.48 (m, 15H, aromatics), 8.08 [bs, 3H, -NH3
+
 (Orn)], 9.15 and 9.78 [2bs, 
2H, -NH2
+ 
(Orn)], 9.65 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.1 (CH2, Cγ), 
27.1 (CH2, Cβ), 28.2 (CH2, C3), 33.5 (CH2, Cδ), 38.0 (CH2, Bn), 42.6 (CH2, C1), 56.7 (CH, 
C2), 59.5 (CH, Cα), 118.1-148.0 (15CH and 3 C, aromatics), 156.2 (HNCONH), 167.0 
(CONH);  ES-MS m/z [M+1]
+
 calcd for C28H35N5O2, 474.28; found, 574.27 (100%). 
4.5.5. N-[(2S)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-ornithine benzyl amide 
dihydrochloride [(S)-17a] 
Amorphous solid (55 mg, 100 %); HPLC tR  12.89 min; [α]D
20
 + 26.6 (c 0.9, MeOH); 
1
H 
NMR (400 MHz, DMSO-d6) δ 1.67-1.78 [m, 2H, γ-H (Orn)], 1.82-2.06 [m, 2H, β-H (Orn)], 
2.74-2.96 [m, 3H, 3-H (Pr) and δ-H (Orn)], 2.99-3.18 [m, 1H, 3-H (Pr)], 3.11 [m, 1H, 1-H 
(Pr)], 3.23 [m, 1H, 2-H (Pr)], 3.53 [m, 1H, 1-H (Pr)], 4.27-4.44 [m, 1H, α-H (Orn)], 4.35 [d, 
2H, J=6.5 Hz, CH2 (Bn)], 6.86-7.45 (m, 15H, aromatics), 6.94 and 7.10 (2bs, 2H, NHCONH), 
8.12 [bs, 3H, -NH3
+
 (Orn)], 9.41 and 9.50 [2bs, 2H, -NH2
+ 
(Orn)], 9.64 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.7 (CH2, Cγ), 27.3 (CH2, Cβ), 34.9 (CH2, C3), 37.7 (CH2, 
Cδ), 38.8 (CH2, Bn), 42.7 (CH2, C1), 57.7 (CH, C2), 59.0 (CH, Cα), 117.8-140.2 (15CH and 3 
C, aromatics), 156.2 (HNCONH), 167.2 (CONH); ES-MS m/z [M+1]
+
 ES-MS m/z [M+1]
+
 
calcd for C28H35N5O2, 474.28; found, 574.52 (100%). 
4.5.6. N-[(2R)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-lysine benzyl amide 
dihydrochloride [(R)-17b] 
Amorphous solid (56 mg, 100%); HPLC tR 12.78 min; [α]D
20 
+ 16.5 (c 1.6, MeOH); 
1
H 
NMR (400 MHz, DMSO-d6) δ 1.25-1.48 [m, 2H, γ-H (Lys)], 1.50-1.70  [m, 2H, δ-H (Lys)], 
1.72-2.08 [m, 2H, β-H (Lys)], 2.72 [m, 2H, ε-H (Lys)], 2.77-2.92 [m, 1H, 3-H (Pr)], 3.08-3.34 
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[m, 3H, 1-H and 3-H (Pr)], 3.24 [m, 1H, 2-H (Pr)], 4.20 [m, 1H, α-H (Lys)], 4.28 [dd, 1H, J= 
6 and 15 Hz, CH2 (Bn)], 4.45 [dd, , 1H, J= 5 and 15 Hz, CH2 (Bn)], 6.89 (bs, 2H, HNCONH), 
7.09-7.49 (m, 15H, aromatics), 8.01 [bs, 3H, -NH3
+
 (Lys)], 9.01 and 9.77 [2bs, 2H, -NH2
+ 
(Lys)], 9.47 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.0 (CH2, Cγ), 27.1 (CH2, 
Cδ), 30.2 (CH2, Cβ), 34.3 (CH2, C3), 38.9 (CH2, Cε), 38.9 (CH2, Bn), 43.3 (CH2, C1), 57.9 
(CH, C2), 60.3 (CH, Cα), 118.9-140.7 (15CH and 3C, aromatics), 157.3 (HNCONH), 167.8 
(CONH); ES-MS m/z [M+1]
+
 calcd for C29H37N5O2, 488.29; found, 488.50 (100%). 
4.5.7. N-[(2S)-3-Phenyl-1-(3-phenylureido)propan-2-yl]-lysine benzyl amide 
dihydrochloride [(S)-17b] 
Amorphous solid (57 mg, 100 %); HPLC tR 13.26 min; [α]D
20 
+19.3 (c 1.5, MeOH); 
1
H 
NMR (400 MHz, DMSO-d6) δ 1.28-1.49 [m, 2H, γ-H (Lys)], 1.51-1.69  [m, 2H, δ-H (Lys)], 
1.74-2.01 [m, 2H, β-H (Lys)], 2.69 [m, 2H, ε-H (Lys)], 2.78-2.94 [m, 1H, 3-H (Pr)], 2.99-3.18 
[m, 2H, 1-H and 3-H (Pr)], 3.23 [m, 1H, 2-H (Pr)], 3.51-3.60 [m, 1H, 1-H (Pr)], 4.23-4.48 [m, 
1H, α-H (Lys)], 4.33 [d, 2H, J= 5 Hz, CH2 (Bn)], 6.80-7.48 [m, 18H, aromatics and -NH3
+
 
(Lys)], 6.89 and 7.15 (2bs, 2H, NHCONH), 9.09 and 9.51 [2bs, 2H, -NH2
+ 
(Lys)], 9.51 (bs, 
1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.1 (CH2, Cγ), 27.0 (CH2, Cδ), 30.4 (CH2, 
Cβ), 35.7 (CH2, C3), 38.5 (CH2, Cε), 38.9 (CH2, Bn), 43.3 (CH2, C1), 58.9 (CH, C2), 59.8 (CH, 
Cα), 118.5-140.9 (15CH and 3C, aromatics), 157.0 (HNCONH), 168.0 (CONH); ES-MS m/z 
[M+1]
+
 calcd for C29H37N5O2, 488.29; found, 488.50 (100%). 
4.5.8. N-[(2R)-1-(3-Benzylureido)-3-phenylpropan-2-yl]-ornithine benzyl amide 
dihydrochloride [(R)-18a] 
Amorphous solid (56 mg, 100 %); HPLC tR 12.87 min; [α]D
20
 +5.2 (c 1, MeOH); 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.56-1.82 [m, 2H, γ-H (Orn)], 1.90-2.10 [m, 2H, β-H (Orn)], 2.74-
3.02 [m, 4H, 3-H (Pr) and δ-H (Orn)], 3.23 [m, 1H, 2-H (Pr)], 3.09-3.22 [m, 2H, 1-H (Pr)], 
4.30 [m, 2H, CH2 (Bn-ureido)], 4.32-4.38 [m,1H, α-H (Orn)], 4.35 [dd, 1H, J= 6.5 and 15 Hz, 
CH2 (Bn)], 4.60 [ dd, 1H, J=5 and 15 Hz, CH2 (Bn)], 6.72 and 7.00 (2bs, 2H, NHCONH), 
7.21-7.65 (m, 15H, aromatics), 8.08 [bs, 3H, -NH3
+
 (Orn)], 9.56 and 9.81 [2bs, 2H, -NH2
+ 
(Orn)], 9.56 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 22.7 (CH2, Cγ), 27.2 (CH2, 
Cβ), 28.9 (CH2, C3), 33.5 (CH2, Cδ), 38.1 (CH2, Bn), 42.6 [CH2, (Bn-ureido)], 43.1 (CH2, C1), 
56.7 (CH, C2), 60.4 (CH, Cα), 126.9-140.2 (15CH and 3C, aromatics), 159.7  (HNCONH), 
166.9 (CONH);  ES-MS m/z [M+1]
+
 calcd for C29H37N5O2, 488.29; found, 488.52 (100%). 
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4.5.9. N-[(2S)-1-(3-Benzylureido)-3-phenylpropan-2-yl]-ornithine benzyl amide 
dihydrochloride [(S)-18a] 
Amorphous solid (55 mg, 100 %); HPLC tR 12. 95 min; [α]D
20
 +2.1 (c 1.5, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.58-1.74 [m, 2H, γ-H (Orn)], 1.80-1.99 [m, 2H, β-H (Orn)], 
2.74-3.10 [m, 5H, 1-H, 3-H (Pr) and δ-H (Orn)], 3.18 [m, 1H, 2-H (Pr)], 3.38-3.46 [m, 1H, 1-
H (Pr)], 4.20 [dd, 1H, J= 6  and 15 Hz, CH2 (Bn-ureido)], 4.28 [d, 2H, J= 6 CH2 (Bn)], 4.32 
[m,1H, α-H (Orn)], 4.41 [dd, 1H, J= 6  and 15 Hz, CH2 (Bn-ureido)], 4.60 [ dd, 1H, J=5 and 
15 Hz, CH2 (Bn)], 6.94 and 7.11 (2bs, 2H, NHCONH), 7.18-7.30 (m, 15H, aromatics), 8.09 
[bs, 3H, -NH3
+
 (Orn)], 9.19 and 9.86 [2bs, 2H, -NH2
+ 
(Orn)], 9.54 (bs, 1H, NH-Bn); 
13
C 
NMR (100 MHz, DMSO-d6) δ 23.3 (CH2, Cγ), 27.9 (CH2, Cβ), 28.8 (CH2, C3), 35.4 (CH2, Cδ), 
38.6 (CH2, Bn), 43.4 [CH2, (Bn-ureido)], 43.7 (CH2, C1), 58.5 (CH, C2), 60.6 (CH, Cα), 127.4-
140.9 (15CH and 3C, aromatics), 160.5 (HNCONH), 167.9 (CONH);  ES-MS m/z [M+1]
+
 
calcd for C29H37N5O2, 488.29; found, 488.38 (100%). 
4.5.10. N-[(2R)-1-(3-(2,4-Dichlorophenyl)ureido)-3-phenylpropan-2-yl]-lysine benzyl amide 
dihydrochloride [(R)-19b] 
Amorphous solid (62 mg, 100 %); HPLC tR 14.85 min; [α]D
20 
+ 9.8 (c 0.4, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.37-1.49 [m, 2H, γ-H (Lys)], 1.53-1.71 [m, 2H, δ-H (Lys)], 
1.82-2.05 [m, 2H, β-H (Lys)], 2.80 [m, 2H, ε -H (Lys)], 2.91 [m, 1H, 3-H (Pr)], 3.23 [m, 1H, 
2-H (Pr)], 3.27-3.40 [m, 3H, 1-H  and 3-H (Pr)], 3.26 [m, 1H, α-H (Lys)], 3.26 [dd, 1H, J= 6 
and 15 Hz, CH2 (Bn)], 4.52 [dd, , 1H, J= 5 and 15 Hz, CH2 (Bn)], 7.18-7.44 (m, 13H, 
aromatics), 7.59 (bs, 2H, HNCONH), 7.94 [bs, 3H, -NH3
+
 (Lys)], 8.99 and 9.67 [2bs, 2H, -
NH2
+ 
(Lys)], 9.43 (bs, 1H, NH-Bn); 
13
C NMR (125 MHz, DMSO-d6) δ 21.3 (CH2, Cγ), 26.5 
(CH2, Cδ), 29.4 (CH2, Cβ), 32.0 (CH2, C3), 37.5 (CH2, Cε), 38.3 (CH2, Bn), 42.6 (CH2, C1), 
57.2 (CH, C2), 58.8 (CH, Cα), 116.9-140.2 (13CH and 5C, aromatics), 155.9 (HNCONH), 
167.1 (CONH); ES-MS m/z [M+1]
+
 calcd for C29H35Cl2N5O2, 556.22; found, 556.63 (100%), 
558.52 (64%) [M+3]
+
, 560.42 (10%) [M+5]
+
. 
4.5.11. N-[(2S)-1-(3-(2,4-Dichlorophenyl)ureido)-3-phenylpropan-2-yl]-lysine benzyl amide 
dihydrochloride [(S)-19b] 
Amorphous solid (63 mg, 100 %); HPLC tR 14.09 min; [α]D
20 
+ 12.3 (c 1.1, MeOH); 
1
H 
NMR (400 MHz, DMSO-d6)  δ 1.17-1.42 [m, 2H, γ-H (Lys)], 1.46-1.681 [m, 2H, δ-H (Lys)], 
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1.68-1.98 [m, 2H, β-H (Lys)], 2.61-2.95 [m, 2H, 3-H (Pr)], 2.71 [m, 2H, ε -H (Lys)],  2.96-
3.19 [m, 2H, 1-H (Pr)], 3.23 [m, 1H, 2-H (Pr)], 4.3 [m, 1H, α-H (Lys)], 4.36 [d, 2H, J= 5 Hz, 
CH2 (Bn)], 7.11-7.39 (m, 15H, aromatics and HNCONH), 7.92 [bs, 3H, -NH3
+
 (Lys)], 9.16 
[bs, 2H, -NH2
+ 
(Lys)], 9.41 (bs, 1H, NH-Bn); 
13
C NMR (100 MHz, DMSO-d6) δ 21.9 (CH2, 
Cγ), 26.9 (CH2, Cδ), 29.5 (CH2, Cβ), 35.0 (CH2, C3), 38.3 (CH2, Bn), 38.8 (CH2, Cε), 43.1 
(CH2, C1), 58.5 (CH, C2), 59.0 (CH, Cα), 116.5-141.5 (13CH and 5C, aromatics), 156.2 
(HNCONH), 167.9 (CONH); ES-MS m/z [M+1]
+
 calcd for C29H35Cl2N5O2, 556.22; found, 
556.63 (100%), 558.52 (64%) [M+3]
+
, 560.42 (10%) [M+5]
+
. 
4.5.12. N-[(2R)-1-(3-(4-Methoxyphenethyl)ureido)-3-phenylpropan-2-yl]-lysine benzyl 
amide dihydrochloride [(R)-20b] 
Amorphous solid (61 mg, 100 %); HPLC tR 13.46 min; [α]D
20 
+15.6 (c 0.8, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.27-1.39 [m, 2H, γ-H (Lys)], 1.39-1.64 [m, 2H, δ-H (Lys)], 
1.74-1.95 [m, 2H, β-H (Lys)], 2.68-2.79 [m, 1H, 3-H (Pr)], 2.63 [t, 2H, J= 7 Hz, 2-H (ethyl)], 
2.71 [m, 2H, ε-H (Lys)], 3.03-3.25 [m, 6H, 1-H, 2-H, 3-H (Pr) and 1-H (ethyl)], 3.69 (s, 3H, 
OMe), 4.09 [m, 1H, α-H (Lys)], 4.28 [dd, 1H, J= 6 and 15 Hz, CH2 (Bn)], 4.47 [dd, 1H, J= 5 
and 15 Hz, CH2 (Bn)], 6.37 and 6.50 (2bs, 2H, HNCONH), 6.69-7.38 (m, 14H, aromatics), 
7.80 [bs, 3H, -NH3
+
 (Lys)], 9.25 [bs, 2H, -NH2
+ 
(Lys)], 9.45 (bs, 1H, NH-Bn); 
13
C NMR 
(125 MHz, DMSO-d6) δ 21.6 (CH2, Cγ), 27.2 (CH2, Cδ), 30.5 (CH2, Cβ), 34.3 (CH2, C3), 35.4 
[CH2, C2 (ethyl)], 38.0 [CH2, Cε and C1 (ethyl)], 38.0 (CH2, Cε), 38.8 (CH2, Bn), 41.9 (CH2, 
C1), 55.4 (CH, C2), 55.4 (CH3, OMe), 56.8 (CH, Cα), 114.0-158.0 (14CH and 4C, aromatics), 
161.5 (HNCONH), 167.9 (CONH); ES-MS m/z [M+1]
+
 calcd for C32H43N5O3, 546.34; found, 
546.62(100%). 
4.5.13. N-[(2S)-1-(3-(4-Methoxyphenethyl)ureido)-3-phenylpropan-2-yl]-lysine benzyl 
amide dihydrochloride [(S)-20b] 
Amorphous solid (62 mg, 100 %); HPLC tR 13.52 min; [α]D
20 
+19.7 (c 0.7, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.35 [m, 2H, γ-H (Lys)], 1.594 [m, 2H, δ-H (Lys)], 1.83 [m, 
2H, β-H (Lys)], 2.62 [m, 2H, ε-H (Lys)], 2.71 [m, 2H, 2-H (ethyl)], 2.96 [m, 1H, 3-H (Pr)], 
3.03 [m, 3H, 1-H and 3-H (Pr)], 3.15 [d, 2H, J= 7 Hz, 1-H (ethyl)], 3.20 [m, 1H, 2-H (Pr)], 
3.69 (s, 3H, OMe), 4.21 [m, 1H, α-H (Lys)], 4.36 [m, 2H, CH2 (Bn)], 6.57 and 6.76 (2bs, 2H, 
HNCONH), 7.14-7.3 (m, 14H, aromatics), 8.03 [bs, 3H, -NH3
+
 (Lys)], 9.00 and 9.92 [2bs, 
2H, -NH2
+ 
(Lys)], 9.45 (bs, 1H, NH-Bn); 
13
C NMR (125 MHz, DMSO-d6) δ 21.3 (CH2, Cγ), 
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26.3 (CH2, Cδ), 29.6 (CH2, Cβ), 34.7 [CH2, C2 (ethyl)], 34.9 (CH2, C3), 38.1 [CH2, C1 (ethyl)], 
38.7 (CH2, Cε), 40.1 (CH2, Bn), 42.6 (CH2, C1), 54.9 (CH3, OMe), 58.4 (CH, C2), 60.0 (CH, 
Cα), 113.8-157.6 (14CH and 4C, aromatics), 159.8 (HNCONH), 167.4 (CONH); ES-MS m/z 
[M+1]
+
 calcd for C32H43N5O3, 546.34; found, 546.62(100%). 
4.5.14. N-[(2R)-1-(3-(4-Fluorophenethyl)ureido)-3-phenyl)propan-2-yl]-lysine benzyl amide 
dihydrochloride [(R)-21b] 
Amorphous solid (60 mg, 100 %); HPLC tR 13.65 min; [α]D
20 
+15.2 (c 0.8, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.30-1.41 [m, 2H, γ-H (Lys)], 1.50-1.67 [m, 2H, δ-H (Lys)], 
1.75-1.98 [m, 2H, β-H (Lys)], 2.68 [t, 2H, J= 7 Hz, 2-H (ethyl)], 2.71 [m, 2H, ε -H (Lys)], 
2.78 [m, 1H, 3-H (Pr)], 3.04 [m, 1H, 2-H (Pr)], 3.08-3.26 [m, 5H, 1-H, 3-H (Pr), and 1-H 
(ethyl)], 4.21 [m, 1H, α-H (Lys)], 4.28 [dd, 1H, J= 6.5 and 15 Hz, CH2 (Bn)], 4.46 [dd, 1H, J= 
5 and 15 Hz, CH2 (Bn)], 6.43 and 6.59 (2bs, 2H, HNCONH), 7.02-7.36 (m, 14H, aromatics), 
7.95 [bs, 3H, -NH3
+
 (Lys)], 9.42 and 9.84 [2bs, 2H, -NH2
+ 
(Lys)], 9.48 (bs, 1H, NH-Bn); 
13
C NMR (75 MHz, DMSO-d6) δ 21.6 (CH2, Cγ), 26.8 (CH2, Cδ), 30.0 (CH2, Cβ), 33.9 (CH2, 
C3),  35.3 [CH2, C2 (ethyl)], 38.2 [CH2, C1 (ethyl)], 38.7 (CH2, Cε), 41.7 (CH2, Bn), 42.9 (CH2, 
C1), 57.6 (CH, C2), 61.2 (CH, Cα), 115.2-160.1 (14CH and 4C, aromatics), 162.2 (HNCONH), 
167.5 (CONH); ES-MS m/z [M+1]
+
 calcd for C31H40FN5O2, 534.32; found, 534.65 (100 %). 
4.5.15. N-[(2S)-1-(3-(4-Fluorophenethyl)ureido)-3-phenyl)propan-2-yl]-lysine benzyl amide 
dihydrochloride [(S)-21b] 
Amorphous solid (59 mg, 100 %); HPLC tR 13.69 min; [α]D
20 
+21.5 (c 1.3, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.36 [m, 2H, γ-H (Lys)], 1.59 [m, 2H, δ-H (Lys)], 1.84 [m, 
2H, β-H (Lys)], 2.68 [t, 2H, J= 7 Hz, 2-H (ethyl)], 2.72 [m, 2H, ε -H (Lys)], 2.78 [m, 1H, 3-H 
(Pr)], 2.97 [m, 1H, 1-H (Pr)], 3.04 [m, 1H, 3-H (Pr)], 3.15 [m, 1H, 2-H (Pr)], 3.18 [m, 1H, 1-
H (Pr)], 3.22 [t, 2H, J= 7 Hz, 1-H (ethyl)], 4.23 [m, 1H, α-H (Lys)], 4.36 [d, 2H, J= 6 Hz, CH2 
(Bn)], 6.63 and 6.82 (2bs, 2H, HNCONH), 7.10-7.34 (m, 14H, aromatics), 8.07 [bs, 3H, -
NH3
+
 (Lys)], 9.02 and 9.91 [2bs, 2H, -NH2
+ 
(Lys)], 9.48 (bs, 1H, NH-Bn); 
13
C NMR (75 
MHz, DMSO-d6) δ 20.1 (CH2, Cγ), 26.7 (CH2, Cδ), 31.8.0 (CH2, Cβ), 35.2 (CH2, C3), 35.5 
[CH2, C2 (ethyl)], 38.7 [CH2, C1 (ethyl)], 39.1 (CH2, Cε), 40.6 (CH2, Bn), 43.0 (CH2, C1), 58.9 
(CH, C2), 60.4 (CH, Cα), 115.4-160.3 (14CH and 4C, aromatics), 162.2 (HNCONH), 167.9 
(CONH); ES-MS m/z [M+1]
+
 calcd for C31H40FN5O2, 534.32; found, 534.65 (100 %). 
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4.6. Synthesis of the indazole-containing protected ureas (R)- and (S)-24b 
Diethyl amine (0.22 mL, 2.1 mmol) was added to a solution of the corresponding Fmoc-
protected amine (R)- and (S)-12b (0.21 mmol) and the reaction mixture was stirred at rt for 2 
h. Then, the solvent was evaporated to dryness and the residue was dissolved in EtOAc (50 
mL). The solution was successively washed with H2O (20 mL) and brine (20 mL), dried over 
Na2SO4, and evaporated to dryness to give the deprotected amines (R)- and (S)- 3b, which 
were reserved. Apart, propylene oxide (118 µL, 1.68 mmol) was added to a 0 ºC cooled 
solution of 1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazole-6-amine [50] (22) 
(79 mg, 0.21 mmol) in dry THF (5 mL). Then, a solution of bis(trichloromethyl)carbonate (20 
mg, 0.07 mmol) in dry THF (1mL) was added dropwise and stirring was maintained  at 0 ºC 
for 15 min. Afterwards, the mixture was added dropwise to a 0 ºC cooled solution of (R)- and 
(S)- 3b (98 mg, 0.21 mmol) in dry THF (5 mL) and stirred for 1 h. Then, the reaction mixture 
was diluted with EtOAc (50 mL), washed successively with H2O (20 mL) and brine (20 mL), 
dried over Na2SO4, and evaporated to dryness. The residue was purified by reversed phase 
chromatography, using 10-100% CH3CN gradient in 0.05 % TFA solution in H2O as mobile 
phase. 
4.6.1. Nε-Boc-N-[(2R)-1-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-
6-yl)ureido)-3-phenylpropan-2-yl]-lysine benzyl amide [(R)-24b] 
Foam (36 mg, 20 %); HPLC tR 16.33 min; HPLC-MS tR 3.26 min; [α]D
20
 +5.6 (c 1, 
MeOH); 
1
H-RMN (400 MHz, CDCl3) δ 1.02-1.46 [m, 4H, γ- and δ-H (Lys)], 1.31 (s, 9H, 
Boc), 1.69, 1.85, 3.02, 3.45 (4m, 8H, pyrrolidine), 1.75-1.94 [m, 2H, β-H (Lys)], 2.74-2.92 
[m, 2H, ε-H (Lys)], 2.74-3.07 [m, 2H, 3-H (Pr)], 3.27 [m, 1H, 2-H (Pr)], 3.21-3.43 [m, 2H, 1-
H (Pr)], 3.93 [bs, 1H, α-H (Lys)], 4.29 [d, J = 7 Hz, 2H, CH2 (Bn)], 4.36 (s, 2H, CH2-
pyrrolidine), 4.64 (s, 1H, NH-Boc), 5.52 (s, 2H, CH2-diClPh), 6.94 [d, J = 7 Hz, 1H, 5-H 
(indazole)], 7.36-7.00 (m, 13H, Ph ), 7.41 [d, J = 7 Hz, 1H, 4-H (indazole)], 7.87 [s, 1H, 7-H 
(indazole)], 8.12 (s, 1H, NH-Bn), 8.72 and 11.8 (2bs, 2H, HNCONH); 
13
C-RMN (100 MHz, 
CDCl3) 21.7 (CH2, Cγ), 23.4 (CH2, pyrrolidine), 28.3 (CH3, Boc), 29.1 (CH2, Cδ), 29.5 (CH2, 
Cβ), 34.9 (CH2, C3), 40.8 (CH2, C1), 43.8 (CH2, Bn), 47.7 (CH2-diClPh), 48.1, 52.3 (CH2, 
pyrrolidine and CH2-pyrrolidine), 59.3 (CH, Cα), 60.2 (CH, C2), 79.5 (C, Boc), 98.8 [C7 
(indazole)], 116.3[C5 (indazole)], 119.2 [C4 (indazole)], 127.6-129.2 (CH, Ph), 130.1 (C, Ph), 
131.2 (C, diClPh), 133.7 [C5 (indazole)], 136.8 (C, Bn), 137.3 (2C, diClPh), 138.8 [C6 
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(indazole)], 141.6 [C7a (indazole)], 157.4 2  (HNCONH), 162.2 (CO, Boc), 167.2 (CONH); 
ES-MS m/z [M+1]
+
 calcd. for C47H58Cl2N8O4, 869.40; found, 435.29 (100%) [(M+2)/2]
+
, 
869.49 (6%) [M+1]
+
. Anal. calcd. for C47H58Cl2N8O4: C, 64.89; H, 6.72; N, 12.88; Found: C, 
64.95; H, 6.82; N, 12.95. 
4.6.2.   Nε-Boc-N-[(2S)-1-(3-(1-(2,6-dichlorobenzyl)-3-(pyrrolidin-1-ylmethyl)-1H-indazol-
6-yl)ureido)-3-phenylpropan-2-yl]-lysine benzyl amide [(S)-24b] 
Foam (155 mg, 85%); HPLC tR 16.51 min; HPLC-MS tR 3.26 min; [α]D
20
 +8.4 (c 1, 
MeOH); 
1
H-RMN (500 MHz, CDCl3) δ 1.08-1.42 [m, 4H, γ- and δ-H (Lys)], 1.29 (s, 9H, 
Boc), 1.70, 1.87, 2.98, 3.45 (4m, 8H, pyrrolidine), 1.76-1.83 [m, 2H, β-H (Lys)], 2.72-2.86 
[m, 2H, ε- H (Lys)], 2.74-3.07 [m, 2H, 3-H (Pr)], 3.23 [m, 1H, 2-H (Pr)], 3.18-3.31 [m, 1H, 1-
H (Pr)], 3.55 [m, 1H, 1-H (Pr)], 4.25 [bs, 1H, α-H (Lys)], 4.30 [dd, J = 5 and 15 Hz, 2H, CH2 
(Bn)], 4.36 (s, 2H, CH2-pyrrolidine), 4.70 (s, 1H, NH-Boc), 5.50 (s, 2H, CH2-diClPh), 6.99 [d, 
J = 7 Hz, 1H, 5-H (indazole)], 7.09-7.34 (m, 13H, Ph), 7.43 [d, J = 7 Hz, 1H, 4-H (indazole)], 
7.80 [s, 1H, 7-H (indazole)], 9.18 (s, 1H, NH-Bn), 8.92 and 11.78 (2bs, 2H, HNCONH); 
13
C-
RMN (125 MHz, CDCl3) δ 21.9 (CH2, Cγ), 23.6 (CH2, pyrrolidine), 28.5 (CH3, Boc), 29.3 
(CH2, Cδ), 30.7 (CH2, Cβ), 30.7 (CH2, Cβ), 36.6 (CH2, C3), 39.7 (CH2, Cε), 40.3 (CH2, C1), 
44.2 (CH2, Bn), 48.0 (CH2-diClPh), 48.6 (CH2-pyrrolidine), 52.8 (CH2, pyrrolidine), 60.6 
(CH, Cα), 61.5 (CH, C2), 79.2 (C, Boc), 98.8 [C7 (indazole)], 116.4 [C5 (indazole)], 119.3 [C4 
(indazole)], 119.8 [C3a (indazole)], 167.6 (CONH), 127.8-129.5 (CH, Ph), 130.5 (C, Ph), 
131.6 (C, diClPh), 133.9 [C5 (indazole)], 134.3 (C, Bn), 137.0 (2C, diClPh), 138.8 [C6 
(indazole)], 141.7 [C7a  (indazole)], 158.5 (C, HNCONH), 162.1 (CO, Boc), 167.6 (CONH); 
ES-MS m/z [M+1]
+
 calcd. for C47H58Cl2N8O4, 869.40; found, 435.29 (100%) [(M+2)/2]
+
, 
869.49 (5%) [M+1]
+
; Anal. calcd. for C47H58Cl2N8O4: C, 64.89; H, 6.72;  N, 12.88; Found: C, 
65.02; H, 6.85; N, 12.92. 
4.6.3.   N-Boc deprotection of (S)-24b. Synthesis of  N-[(2S)-1-(3-(1-(2,6-dichlorobenzyl)-
3-(pyrrolidin-1-ylmethyl)-1H-indazol-6-yl)ureido)-3-phenylpropan-2-yl]-lysine benzyl 
amide trihydrochloride [(S)-25b] 
The protected urea (S)-24b (130 mg, 0.15 mmol) was dissolved in a 3M solution of HCl in 
EtOAc (2 mL) and stirred at rt for 2 h. Then, the solvent was evaporated under reduced 
pressure, the residue was dissolved in H2O (3 mL) and the solution was lyophilized to give 
the urea (S)-25b (131 mg, 100%). HPLC tR 13.11 min; HPLC-MS tR 2.73 min; [α]D
20
 +1.6 (c 
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1.2, MeOH); 
1
H-RMN (500 MHz, DMSO-d6) δ (ppm): 1.32 [m, 2H, γ-H (Lys)], 1.53 [m, 2H, 
δ-H (Lys)], 1.74 [m, 2H, β-H (Lys)], 1.77-1.95 [m, 4H, 2CH2 (pyrrolidine)], 2.66 [m, 2H, ε-H 
(Lys)], 2.84 [dd, 1H, J = 10 and 13 Hz , 3-H (Pr)], 3.04 [m, 4H, 2CH2 (pyrrolidine)], 3.08-
3.16 [m, 1H, 3-H (Pr)], 3.12 [m, 1H, 2-H (Pr)], 3.19-3.59 [m, 2H, 1-H (Pr)], 4.14 [m, 1H, α-H 
(Lys)], 4.32 [t, 2H, J = 7 Hz, CH2 (Bn)], 4.54 (s, 2H, CH2-pyrrolidine), 5.57 (s, 2H, CH2-
diClPh), 7.02-7.95 (m, 16H, aromatics), 8.01 and  9.66 (2s, 2H, HNCONH), 9.08 (s, 1H, NH-
Bn), 9.43 and 10.58 [2bs, 2H, -NH2
+ 
(Lys)].
13
C-RMN (125 MHz, DMSO-d6) δ (ppm): 21.4 
(CH2, Cγ), 22.6 (2CH2, pyrrolidine), 26.4 (CH2, Cδ), 29.7 (CH2, Cβ), 35.1 (CH2, C3), 38.2 
(CH2, Cε), 38.3 (CH2, C1), 42.6 (CH2, Bn), 47.4 (CH2, diClPh), 47.7 (CH2, CH2-pyrrolidine), 
52.7 (2CH2, pyrrolidine), 58.2 (CH, Cα), 58.8 (CH, C2), 98.4 [C7 (indazole)], 114.6 [C5 
(indazole)], 117.8 [C4 (indazole)], 120.6 [C3a (indazole)], 127.1-131.4 (CH, aromatics), 135.5 
(C, Bn),  136.1 (C, diClPh), 136.2 (C, Ph),  138.2 [C5 (indazole)], 138.4 (2C, diClPh), 139.7 
[C6 (indazole)], 141.3 [C7a (indazole)], 156.1 (HNCONH), 167.3 (CONH); ES-MS m/z 
[M+1]
+
 calcd for C42H50Cl2N8O2, 769.34; found, 385.28 (60%) [(M+2)/2]
+
, 769.37 (6%) 
[M+1]
+
. 
4.7. General procedure for the synthesis of thioureas (R)- and (S)-26a 
Diethyl amine (0.32 mL, 3 mmol) was added to a solution of the corresponding Fmoc-
protected amine (R)- and (S)-12a (0.3 mmol) and the reaction mixture was stirred at rt for 2 h. 
Then, the solvent was evaporated to dryness and the residue was dissolved in EtOAc (50 mL). 
The solution was successively washed with H2O (20 mL) and brine (20 mL), dried over 
Na2SO4, and evaporated to dryness to give the deprotected amines (R)- and (S)- 3a. These 
amines were dissolved in dry CH2Cl2 (10 mL) and the solution was cooled at 0ºC. Phenyl 
isothiocyanate (40.5 mg, 0.3 mmol) was added and the mixture was stirred for 2 h. Then, the 
solvent was evaporated and the residue was dissolved in EtOAc (50 mL). This solution was 
successively washed with H2O (20 mL) and brine (20 mL), dried over Na2SO4, and 
evaporated to dryness. The residue was purified by flash chromatography, using 20-100% 
EtOAc gradient in hexane as eluant to give the corresponding thiourea (R)- and (S)-26a. 
4.7.1. N-Boc-N-[(2R)-3-Phenyl-1-(3-phenylthioureido)propan-2-yl]-ornithine benzyl 
amide [(R)-26a] 
Foam (121 mg, 68%); HPLC tR 18.42 min; [α]D
20
 +3.0 (c 1, MeOH); 
1
H NMR (500 MHz, 
CDCl3) δ 1.38 (m, 9H, Boc), 1.10-1.65 [m, 4H, β-H and γ-H (Orn)], 2.71-2.91 [m, 3H, 3-H 
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(Pr) and δ-H (Orn)], 2.97 [dd, 1H, J = 7.5 and 13Hz, 3-H (Pr)], 3.09-3.30 [m, 2H, α-H (Orn) 
and 2-H (Pr)], 3.63 [d, 2H, J = 5Hz, 1-H (Pr)], 4.21 [dd, J = 6.5 and 15Hz, 1H, CH2 (Bn)], 
4.43 [dd, 1H, J = 5 and 15Hz, CH2 (Bn)], 4.53 (s, 1H, NH-Boc), 6.79 and 7.85 (2s, 2H, 
HnCSNH), 7.04-7.63 (m, 16H, aromatics and NH-Bn); 
13
C NMR (125 MHz, CDCl3) δ 25.9 
(CH2, Cγ), 28.3 (CH3, Boc), 30.5 (CH2, Cβ), 39.4 (CH2, Cδ), 43.2 (CH2, Bn), 58.1 (CH, Cα), 
59.7 (CH, C2), 79.3 (C, Boc), 125.0-138.3 (15 CH and 3 C, aromatics), 156.3 (CO, Boc),  
174.9 (CONH), 181.2 (CS); ES-MS m/z [M+1]
+
 calcd. for C33H44N5O3S, 590.31; found, 
590.51 (100 %). Anal. calcd. for C33H43N5O3S: C, 67.20; H, 7.35; N, 11.87; Found: C, 67.24; 
H, 7.55 ; N, 11.93. 
4.7.2. N-Boc-N-[(2S)-3-Phenyl-1-(3-phenylthioureido)propan-2-yl]-ornithine benzyl 
amide [(S)-26a] 
Foam (127 mg, 72%); HPLC tR 18.67 min; [α]D
20
 +7.5 (c 1.1, MeOH); 
1
H NMR (500 
MHz, CDCl3) δ 1.38 (s, 9H, Boc), 1.23-1.90 [m, 4H, β-H and γ-H (Orn)], 2.87-3.17 [m, 6H, 
1- and 3-H (Pr), and δ-H (Orn)], 3.40 [m, 1H, 2-H (Pr)], 3.62 [m,1H, α-H (Orn)], 4.10 [dd, J = 
7 and 15Hz, 1H, CH2 (Bn)], 4.38 [dd, J = 5 and 15Hz, 1H, CH2 (Bn)], 4.71 (s, 1H, NH-Boc), 
6.69 and 8.05 (2s, 2H, HNCSNH),  7.02-7.54 (m, 16H, aromatics and NH-Bn); 
13
C NMR (125 
MHz, CDCl3) δ 26.2 (CH2, Cγ), 28.4 (CH3, Boc),  29.3 (CH2, Cβ), 39.5 (CH2, Cδ), 40.5 (CH2, 
C3), 43.1 (CH2, Bn), 58.3 (CH, Cα), 59.3 (CH, C2), 79.5 (C, Boc), 124.5-138.4 (15CH and 3C, 
aromatics), 156.4 (CO, Boc), 173.4 (CONH), 181.3 (CS); ES-MS m/z [M+1]
+
 calcd. for 
C33H43N5O3S, 590.31; found, 590.58 (100%). Anal. calcd. for C33H43N5O3S: C, 67.20; H, 
7.35; N, 11.87; Found: C, 67.15; H, 7.45; N, 11.86. 
4.8. N-Boc-deprotection of (R)- and (S)-26a. Synthesis of the thiourea hydrochlorides (R)- 
and (S)-27a 
It was carried out by applying the above described methodology for N-Boc removal in the 
urea analogues. 
4.8.1. N-[(2R)-3-Phenyl-1-(3-phenylthioureido)propan-2-yl]-ornithine benzyl amide 
dihydrochloride [(R)-27a] 
Amorphous solid (56 mg, 100%); HPLC tR 13.29 min; [α]D
20
 +10.7 (c 1, MeOH); 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.50-1.76 [m, 2H, γ-H (Orn)], 1.78-2.06 [m, 2H, β-H (Orn)], 2.72-
3.27 [m, 4H, 3-H (Pr) and δ-H (Orn)], 3.46-3.66 [m, 2H, 1-H (Pr)], 3.80 [m, 1H, 2-H (Pr)], 
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4.25 [dd, 1H, J=6 and 15 Hz, CH2(Bn)], 4.37 [m, 1H, α-H (Orn)], 4.53 [dd, 1H, J = 5 and 15 
Hz, CH2(Bn)], 7.10 (s,1H, HNCSNH), 6.93-7.55(m, 16H, aromatics and HNCSNH), 8.05 [bs, 
3H, -NH3
+
 (Orn)], 8.75 and 10.22 [2bs, 2H, -NH2
+ 
(Orn)], 9.41(s, 1H, NH-Bn); 
13
C NMR 
(125 MHz, DMSO-d6) δ 22.8 (CH2, Cγ), 27.1 (CH2, Cβ), 28.2 (CH2, C3), 34.1 (CH2,Cδ), 38.1 
(CH2, Bn), 42.7 (CH2, C1), 57.0 (CH, C2), 58.3 (CH, Cα),117.7-139.9 (15CH and 3C, 
aromatics), 166.9 (CONH), 181.0 (CS); ES-MS m/z [M+1]
+
 calcd. for C28H35N5OS, 490.26; 
found 246.13(100%) [(M+2)/2]
+
, 490.48 (15%) [M+1]
+
. 
4.8.2. N-[(2S)-3-Phenyl-1-(3-phenylthioureido)propan-2-yl]-ornithine benzyl amide 
dihydrochloride [(S)-27a] 
Amorphous solid (54 mg, 100%); HPLC tR 13.40 min; [α]D
20
 +2.9 (c 0.7, MeOH); 
1
H 
NMR (500 MHz, DMSO-d6) δ 1.51-2.06 [m, 4H, β- and γ-H (Orn)], 2.73-3.22 [m, 5H, 2- and 
3-H (Pr), and δ-H (Orn)], 3.52-3.60 [m, 2H, 1-H (Pr)], 4.29 [m, 1H, α-H (Orn)], 4.40 [d, 2H, J 
= 6 Hz, CH2 (Bn], 7.10 (s, 1H, HNCSNH), 6.69-7.71 (m, 15H, aromatics and HNCSNH), 
7.94 [bs, 3H, -NH3
+
 (Orn)], 9.42 (s, 1H, NH-Bn), 9.19 and 9.54 [2bs, 2H, -NH2
+ 
(Orn)]; 
13
C 
NMR (125 MHz, DMSO-d6) δ 22.7 (CH2, Cγ), 27.1 (CH2, Cβ), 31.6 (CH2, C3), 38.3 (CH2,Cδ), 
38.9 (CH2, Bn), 42.8 (CH2, C1), 57.0 (CH, C2), 58.8 (CH, Cα), 123.4-138.7 (15CH and 3C, 
aromatics), 166.9 (CONH), 181.7 (CS); ES-MS m/z [M+1]
+
 calcd. for C28H35N5OS, 490.26; 
found 246.13 (100%) [(M+2)/2]
+
, 490.48 (15%) [M+1]
+
. 
4.9. Platelet aggregation inhibition assay 
Whole blood was obtained from human volunteers  who were not taking any platelet 
altering drugs for two weeks prior to donation. Blood was collected by venous puncture into 
2.7 mL vacutainer tubes containing 3.2% buffered sodium citrate. Blood was centrifuged at 
250×g for 7 min to obtain platelet rich plasma (PRP). After removal of PRP, the blood was re-
centrifuged at 900×g for 10 min to obtain platelet poor plasma (PPP). The PPP was used as a 
reference in the optical aggregation and as a diluent to achieve a final platelet concentration of 
200.000 platelet/μL in PRP. Tests were performed in an optical aggregometer (Chrono-Log 
Model 440 Four Channel). Briefly, a 0.5 mL sample of diluted PRP was added to a glass 
cuvette and incubated with either vehicle (DMSO solution) or tested compound, at a 0.1 
mg/mL concentration, for 5 min at 37 ºC. At the beginning of each experiment, aggregation 
response to SFLLRN (30μM) was evaluated and the maximum aggregation value at the end 
of 5 min was recorded. Aggregation response to SFLLRN plus compound was recorded and 
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compared to control (SFLLRN/vehicle) to determine the % of inhibition. Each compound was 
tested twice and the results are the mean of the two assays. 
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